US20110144098A1 - Amino oxazine derivatives - Google Patents

Amino oxazine derivatives Download PDF

Info

Publication number
US20110144098A1
US20110144098A1 US12/958,436 US95843610A US2011144098A1 US 20110144098 A1 US20110144098 A1 US 20110144098A1 US 95843610 A US95843610 A US 95843610A US 2011144098 A1 US2011144098 A1 US 2011144098A1
Authority
US
United States
Prior art keywords
methyl
amino
phenyl
fluoro
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/958,436
Other versions
US7964594B1 (en
Inventor
David Banner
Hans Hilpert
Harald Mauser
Alexander V. Mayweg
Mark Rogers-Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann La Roche Inc
Original Assignee
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche Inc filed Critical Hoffmann La Roche Inc
Assigned to HOFFMANN-LA ROCHE, INC. reassignment HOFFMANN-LA ROCHE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: F. HOFFMANN-LA ROCHE AG
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BANNER, DAVID, HILPERT, HANS, MAUSER, HARALD, MAYWEG, ALEXANDER V., ROGERS-EVANS, MARK
Publication of US20110144098A1 publication Critical patent/US20110144098A1/en
Application granted granted Critical
Publication of US7964594B1 publication Critical patent/US7964594B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • the present invention relates to compounds useful in the treatment of type 2 diabetes and other metabolic disorders.
  • Type 2 diabetes is caused by insulin resistance and inadequate insulin secretion from pancreatic beta-cells leading to poor blood-glucose control and hyperglycemia (M Prentki & C J Nolan, “Islet beta-cell failure in type 2 diabetes.” J. Clin. Investig. 2006, 116(7), 1802-1812).
  • Patients with T2D have an increased risk of microvascular and macrovascular disease and a range of related complications including diabetic nephropathy, retinopathy and cardiovascular disease. In 2000 an estimated 171 million people had the condition with the expectation that this figure will double by 2030 (S Wild, G Roglic, A Green, R.
  • Tmem27 has been identified as a protein promoting beta-cell proliferation (P Akpinar, S Kuwajima, J Kriitzfeldt, M Stoffel, “Tmem27: A cleaved and shed plasma membrane protein that stimulates pancreatic (3 cell proliferation”, Cell Metab. 2005, 2, 385-397) and insulin secretion (K Fukui, Q Yang, Y Cao, N Takahashi et al., “The HNF-1 target Collectrin controls insulin exocytosis by SNARE complex formation”, Cell Metab. 2005, 2, 373-384).
  • Tmem27 is a 42 kDa membrane glycoprotein which is constitutively shed from the surface of beta-cells, resulting from a degradation of the full-length cellular Tmem27.
  • Overexpression of Tmem27 in a transgenic mouse increases beta-cell mass and improves glucose tolerance in a DIO model of diabetes [K Fukui, Q Yang, Y Cao, N Takahashi et al., “The HNF-1 target Collectrin controls insulin exocytosis by SNARE complex formation”, Cell Metab.
  • Tmem27 A cleaved and shed plasma membrane protein that stimulates pancreatic ⁇ cell proliferation”, Cell Metab. 2005, 2, 385-397.
  • siRNA knockout of Tmem27 in a rodent beta-cell proliferation assay reduces the proliferation rate, indicating a role for Tmem27 in control of beta-cell mass.
  • BACE2 cleaves a peptide based on the sequence of Tmem27.
  • the closely related protease BACE1 does not cleave this peptide and selective inhibition of BACE1 alone does not enhance proliferation of beta-cells.
  • BACE1 (BACE for beta-site APP-cleaving enzyme, also known as beta-secretase) has been implicated in the pathogenesis of Alzheimer disease and in the formation of myelin sheaths in peripheral nerve cells.
  • BACE2 The close homolog BACE2 is a membrane-bound aspartyl protease and is colocalised with Tmem27 in rodent pancreatic beta-cells (G Finzi, F Franzi, C Placidi, F Acquati et al., “BACE2 is stored in secretory granules of mouse and rat pancreatic beta cells”, Ultrastruct Pathol. 2008, 32(6), 246-251). It is also known to be capable of degrading APP (I Hussain, D Powell, D Howlett, G Chapman et al., “ASP1 (BACE2) cleaves the amyloid precursor protein at the ⁇ -secretase site” Mol Cell Neurosci.
  • IL-1R2 P Kuhn, E Marjaux, A Imhof, B De Strooper et al., “Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase” J. Biol. Chem. 2007, 282(16), 11982-11995).
  • BACE2 Inhibition of BACE2 is therefore proposed as a treatment for type 2 diabetes with the potential to preserve and restore beta-cell mass and stimulate insulin secretion in pre-diabetic and diabetic patients. It is therefore an object of the present invention to provide selective BACE2 inhibitors. Such compounds are useful as therapeutically active substances, particularly in the treatment and/or prevention of diseases which are associated with the inhibition of BACE2.
  • the compounds of the present invention exceed the compounds known in the art, inasmuch as they are strong and selective inhibitors of BACE2. They are expected to have an enhanced therapeutic potential compared to the compounds already known in the art and can be used for the treatment and prevention of diabetes, particularly type 2 diabetes, metabolic syndrome and a wide range of metabolic disorders.
  • the present invention relates to compounds of formula I,
  • the invention is also concerned with the manufacture of compounds of formula I, with pharmaceutical compositions containing them and their use as medicaments.
  • the compounds of formula I are inhibitors of BACE2 and may therefore be useful in the treatment of type 2 diabetes and other metabolic disorders.
  • compound(s) of this invention and “compound(s) of the present invention” refers to compounds of formula I and stereoisomers, tautomers, solvates, and salts (e.g., pharmaceutically acceptable salts) thereof.
  • Structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example wherein one or more hydrogen atoms are replaced by deuterium, or one or more carbon atoms are replaced by a 13C- or 14C-enriched carbon are within the scope of this invention.
  • halogen refers to fluorine (fluoro, F), chlorine (chloro, Cl), bromine (bromo, Br) and iodine (iodo, I), with fluorine, chlorine and bromine being particular, and with fluorine and chlorine being more particular. Most particular is F.
  • lower alkyl or “C 1-7 -alkyl”, alone or in combination, signifies a straight-chain or branched-chain alkyl group with 1 to 7 carbon atoms, particularly a straight or branched-chain alkyl group with 1 to 6 carbon atoms and particularly particular a straight or branched-chain alkyl group with 1 to 4 carbon atoms.
  • Examples of straight-chain and branched C 1-7 alkyl groups are methyl (Me), ethyl (Et), propyl, isopropyl, butyl, isobutyl, tert.-butyl, the isomeric pentyls, the isomeric hexyls and the isomeric heptyls, particularly methyl and ethyl and most particular methyl.
  • lower alkoxy or “C 1-7 -alkoxy” refers to the group R′—O—, wherein R′ is lower alkyl and the term “lower alkyl” has the previously given significance.
  • lower alkoxy groups are methoxy (MeO, OMe), ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy and tert.-butoxy, particularly methoxy and ethoxy.
  • lower halogenalkyl or “halogen-C 1-7 -alkyl” refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a halogen atom, particularly fluoro or chloro, most particularly fluoro.
  • halogen atom particularly fluoro or chloro, most particularly fluoro.
  • the particular lower halogenalkyl groups are trifluoromethyl, difluoromethyl, trifluoroethyl, 2,2-difluoroethyl, fluoromethyl and chloromethyl, with trifluoromethyl or difluoromethyl being especially particular.
  • lower halogenalkoxy or “halogen-C 1-7 -alkoxy” refers to lower alkoxy groups as defined above wherein at least one of the hydrogen atoms of the lower alkoxy group is replaced by a halogen atom, particularly fluoro or chloro, most particularly fluoro.
  • halogenated lower alkoxy groups are trifluoromethoxy, difluoromethoxy, fluormethoxy and chloromethoxy, with trifluoromethoxy being especially particular.
  • lower hydroxyalkyl or “hydroxy-C 1-7 -alkyl” refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a hydroxy group.
  • lower hydroxyalkyl groups are hydroxymethyl or hydroxyethyl.
  • oxo means the group “ ⁇ O” bound to a ring atom.
  • cycloalkyl or “C 3-7 -cycloalkyl” denotes a saturated carbocyclic group containing from 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Especially particular are cyclopropyl, cyclobutyl and cyclopentyl. Specific is cyclopropyl.
  • 3- to 7-membered O-heterocyclyl ring denotes a saturated 3- to 7-membered heterocyclyl ring containing at least one oxygen atom, such as oxirane, oxetane, tetrahydrofurane, tetrahydropurane and oxepane.
  • a tetrahydrofurane (furyl) ring is particular. Specific is oxetanyl.
  • aryl refers to an aromatic monocyclic or multicyclic ring system having 6 to 14 carbon atoms, particularly 6 to 10 carbon atoms. Particular aryl groups are phenyl and naphthyl, with phenyl being most particular.
  • heteroaryl refers to an aromatic or partly unsaturated 5- or 6-membered ring which comprises at least one heteroatom selected from nitrogen, oxygen and/or sulphur, and can in addition comprise one or three atoms selected from nitrogen, oxygen and/or sulphur, such as pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 6-oxo-1,6-dihydropyridazinyl, 5-oxo-4,5-dihydropyrazinyl, pyrrolyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyrazolyl, imidazolyl, triazolyl and thiazolyl.
  • heteroaryl further refers to bicyclic aromatic or partly unsaturated groups comprising two 5- or 6-membered rings, in which one or both rings can contain one, two or three atoms selected from nitrogen, oxygen or sulphur, such as quinolinyl, isoquinolinyl, cinnolinyl, pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, thieno[2,3-c]pyridyl, quinoxalinyl, benzo[b]thienyl, benzothiazolyl, benzotriazolyl, indolyl, indazolyl and 3,4-dihydro-1H-isoquinolinyl.
  • heteroaryl groups are thienyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, 6-oxo-1,6-dihydropyridazinyl, 5-oxo-4,5-dihydropyrazinyl and imidazo[1,2-a]pyridyl, with thienyl, oxazolyl, pyrazolyl, pyridyl, pyrimidinyl and pyrazinyl being more particular and pyridyl being most particular.
  • compositions of formula I can form pharmaceutically acceptable salts.
  • pharmaceutically acceptable salts refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable.
  • the pharmaceutically acceptable salts of the compounds of formula I are the acid addition salts with physiologically compatible mineral acids, such as hydrochloric acid, sulfuric acid, sulfurous acid or phosphoric acid; or with organic acids, such as methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxylic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, malonic acid, tartaric acid, benzoic acid, cinnamic acid, mandelic acid, succinic acid or salicylic acid.
  • Particularly particular pharmaceutically acceptable salts of compounds of formula I are the acid addition salts such
  • the compounds of formula I can also be solvated, e.g., hydrated.
  • the solvation can be effected in the course of the manufacturing process or can take place e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of formula I (hydration).
  • pharmaceutically acceptable salts also includes physiologically acceptable solvates.
  • “Isomers” are compounds that have identical molecular formulae but that differ in the nature or the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereoisomers”, and stereoisomers that are non-superimposable mirror images are termed “enantiomers”, or sometimes optical isomers. A carbon atom bonded to four non-identical substituents is termed a “chiral center”.
  • Chiral molecules are optically active, i.e., they have the ability to rotate the plane of plane-polarized light.
  • Compounds of present invention can have one or more chiral centers and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. Whenever a chiral center is present in a chemical structure, it is intended that all stereoisomers associated with that chiral center are encompassed by the present invention.
  • the invention relates to compounds of formula I, wherein
  • the invention relates to compounds of formula I, wherein
  • the invention relates to compounds of formula I as herein described, wherein R 1 and R 2 together with the C atom they are attached to form a C 3-7 -cycloalkyl ring.
  • the invention relates to compounds of formula I as herein described, wherein R 2 and R 3 together with the C atom they are attached to form a C 3-7 -cycloalkyl ring.
  • the invention relates to compounds of formula I as herein described, wherein R 2 and R 3 together with the C atom they are attached to form furyl.
  • the invention relates to compounds of formula I as herein described, wherein R 1 and R 2 together with the C atom they are attached to form a cyclopropyl.
  • the invention relates to compounds of formula I as herein described, wherein R 1 and R 2 are each hydrogen.
  • the invention relates to compounds of formula I as herein described, wherein R 1 is hydrogen.
  • the invention relates to compounds of formula I as herein described, wherein R 2 is hydrogen.
  • the invention relates to compounds of formula I as herein described, wherein R 3 is C 1-7 -alkyl.
  • the invention relates to compounds of formula I as herein described, wherein R 3 is methyl.
  • the invention relates to compounds of formula I as herein described, wherein R 3 is ethyl.
  • the invention relates to compounds of formula I as herein described, wherein R 4 is hydrogen or halogen.
  • the invention relates to compounds of formula I as herein described, wherein R 4 is halogen.
  • the invention relates to compounds of formula I as herein described, wherein R 4 is fluoro.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is heteroaryl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, halogen-C 1-7 -alkoxy, cyano, hydroxy-C 1-7 -alkyl, oxo and phenyl.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is heteroaryl selected from the group consisting of pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 6-oxo-1,6-dihydropyridazinyl, 5-oxo-4,5-dihydropyrazinyl, pyrrolyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, thieno[2,3-c]pyridyl, quinoxalinyl, benzo
  • the invention relates to compounds of formula I as herein described, wherein R 5 is heteroaryl selected from the group consisting of thienyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, 6-oxo-1,6-dihydropyridazinyl, 5-oxo-4,5-dihydropyrazinyl and imidazo[1,2-a]pyridyl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, halogen-C 1-7 -alkoxy, cyano, hydroxy-C 1-7 -alkyl, oxo and phenyl.
  • R 5 is heteroaryl selected from the group consisting of thienyl, oxazo
  • the invention relates to compounds of formula I as herein described, wherein R 5 is heteroaryl selected from the group consisting of thienyl, oxazolyl, pyridyl, pyrimidinyl and pyrazinyl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, halogen-C 1-7 -alkoxy, cyano, hydroxy-C 1-7 -alkyl, oxo and phenyl.
  • R 5 is heteroaryl selected from the group consisting of thienyl, oxazolyl, pyridyl, pyrimidinyl and pyrazinyl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C 1-7 -alkyl, halogen
  • the invention relates to compounds of formula I as herein described, wherein R 5 is heteroaryl selected from the group consisting of thienyl, oxazolyl, pyridyl, pyrimidinyl and pyrazinyl substituted by one, two or three groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, halogen-C 1-7 -alkoxy, cyano, hydroxy-C 1-7 -alkyl, oxo and phenyl.
  • R 5 is heteroaryl selected from the group consisting of thienyl, oxazolyl, pyridyl, pyrimidinyl and pyrazinyl substituted by one, two or three groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, halogen
  • the invention relates to compounds of formula I as herein described, wherein R 5 is heteroaryl selected from the group consisting of 1H-pyrazolyl, benzo[b]thiophenyl, isoxazolyl, oxazolyl, pyrazinyl, pyridinyl, pyrimidinyl, thiazolyl, thieno[2,3-c]pyridinyl and thiophenyl, said heteroaryl being unsubstituted or substituted by one or two groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkoxy, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, cyano and phenyl.
  • R 5 is heteroaryl selected from the group consisting of 1H-pyrazolyl, benzo[b]thiophenyl, isoxazolyl, oxazolyl, pyrazinyl, pyridin
  • the invention relates to compounds of formula I as herein described, wherein R 5 is heteroaryl selected from the group consisting of 1H-pyrazolyl, thiazolyl, oxazolyl, pyridinyl, substituted by one or two substituents selected from the group consisting of C 1-7 -alkyl, halogen and cyano.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is 1H-pyrazolyl.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is thiazolyl.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is oxazolyl.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is pyridinyl.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is heteroaryl selected from the group consisting of 1H-pyrazole-3-yl, benzo[b]thiophene-2-yl, isoxazole-3-yl, oxazole-4-yl, pyrazine-2-yl, pyridine-2-yl, pyrimidine-2-yl, thiazol-4-yl, thieno[2,3-c]pyridine-7-yl and thiophene-2-yl, said heteroaryl being unsubstituted or substituted by one or two groups selected from the group consisting of methyl, fluoro, chloro, difluoromethoxy, trifluoroethoxy, trifluoromethyl, methoxy, cyano and phenyl.
  • R 5 is heteroaryl selected from the group consisting of 1H-pyrazole-3-yl, benzo[b]thiophene-2-yl, isoxazole-3-
  • the invention relates to compounds of formula I as herein described, wherein R 5 is phenyl, said phenyl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, halogen-C 1-7 -alkoxy, cyano, hydroxy-C 1-7 -alkyl, oxo and phenyl.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is phenyl, substituted by one or two halogens.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is C 1-7 -alkyl, unsubstituted or substituted by one, two, three, four or five halogens.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is ethyl, substituted by one, two, three, four or five fluoros.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is C 3-7 -cycloalkyl ring, unsubstituted or substituted by one, two or three groups selected from the group consisting of halogen and halogen-C 1-7 -alkyl.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is cyclopropyl, by one or two groups selected from the group consisting of fluoro and trifluoromethyl.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is 3- to 7-membered O-heterocyclyl ring, unsubstituted or substituted by one, two or three groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, halogen-C 1-7 -alkoxy, cyano and hydroxy-C 1-7 -alkyl.
  • the invention relates to compounds of formula I as herein described, wherein R 5 is oxetanyl, substituted by methyl.
  • the invention relates to compounds of formula I as herein described, selected from the group consisting of
  • the invention relates to compounds of formula I as herein described, selected from the group consisting of
  • the invention relates to compounds of formula I as herein described, selected from the group consisting of
  • the invention relates to compounds of formula I as herein described, selected from the group consisting of
  • the invention relates to a process of synthesizing compounds of formula I as herein described, which process comprises reacting an amine of the formula II
  • R 1 to R 4 are as defined herein and Boc is the protecting group tert-butyloxycarbonyl, with a carboxylic acid of the formula III
  • R 1 to R 5 are as defined herein.
  • the invention relates to pharmaceutical compositions comprising a compound of formula I as described herein and a pharmaceutically acceptable carrier and/or adjuvant.
  • the invention relates to compounds of formula I as described herein for use as medicaments.
  • the invention relates to compounds of formula I as described herein for use as medicaments for the treatment or prevention of diseases which are associated with inhibition of BACE2 activity.
  • the invention relates to compounds of formula I as described herein for use as medicaments for the treatment or prevention of diabetes, particularly type 2 diabetes.
  • the invention relates to compounds of formula I as described herein for use as medicaments for the treatment or prevention of type 2 diabetes.
  • the invention relates to a method for the treatment of diseases which are associated with the inhibition of BACE 2 activity, particularly for the treatment of type 2 diabetes, which method comprises administering a therapeutically active amount of a compound of formula I as described herein to a human being or animal.
  • the invention relates to the use of compounds of formula I as described herein for the preparation of medicaments for the treatment or prevention of diseases which are associated with the inhibition of BACE2 activity.
  • the invention relates to the use of compounds of formula I as described herein for the preparation of medicaments for the treatment or prevention of diabetes, particularly type 2 diabetes.
  • R 3 signifies C 1-7 -alkyl.
  • Compounds of formula I of the present invention are particular, wherein R 3 is methyl or ethyl.
  • Another group of particular compounds are those, wherein or R 2 and R 3 together with the C atoms they are attached to form a C 3-7 -cycloalkyl or a 3- to 7-membered O-heterocyclyl ring, with those compounds being more particular, wherein R 2 and R 3 together with the C atoms they are attached to form a 3- to 7-membered O-heterocyclyl ring.
  • compounds of formula I according to the invention are particular, wherein R 4 is hydrogen or halogen. More particularly, R 4 is halogen. Especially particular are compounds of formula I, wherein R 4 is hydrogen or fluoro, with those compounds of formula I, wherein R 4 is fluoro being most particular.
  • compounds of formula I according to the present invention are particular, wherein R 5 is heteroaryl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C 1-7 -alkyl, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, halogen-C 1-7 -alkoxy, cyano, hydroxy-C 1-7 -alkyl, oxo and phenyl.
  • Compounds of formula I possess one asymmetric carbon atom and can exist in the form of optically pure enantiomers and mixtures of enantiomers such as, for example, racemates.
  • the optically active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbens or eluant).
  • the invention embraces all of these forms.
  • the compounds of general formula I in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
  • Physiologically acceptable and metabolically labile derivatives, which are capable of producing the parent compounds of general formula I in vivo are also within the scope of this invention.
  • protecting group denotes the group which selectively blocks a reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry.
  • Protecting groups can be removed at the appropriate point.
  • Exemplary protecting groups are amino-protecting groups, carboxy-protecting groups or hydroxy-protecting groups.
  • protecting group in context with amines denotes groups intended to protect an amino group and includes benzyl, benzyloxycarbonyl (carbobenzyloxy, CBZ), Fmoc (9-Fluorenylmethyloxycarbonyl), p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, tert-butoxycarbonyl (BOC), and trifluoroacetyl. Further examples of these groups are found in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, 2nd ed., John Wiley & Sons, Inc., New York, N.Y., 1991, chapter 7; E.
  • IC50 half maximal inhibitory concentration
  • IC50 values can be converted logarithmically to pIC50 values ( ⁇ log IC50), in which higher values indicate exponentially greater potency.
  • the IC50 value is not an absolute value but depends on experimental conditions e.g. concentrations employed.
  • the IC50 value can be converted to an absolute inhibition constant (Ki) using the Cheng-Prusoff equation (Biochem. Pharmacol. (1973) 22:3099).
  • inhibitor denotes a compound which competes with, reduces or prevents the binding of a particular ligand to particular receptor or which reduces or prevents the inhibition of the function of a particular protein.
  • therapeutically effective amount denotes an amount of a compound of the present invention that, when administered to a subject, (i) treats or prevents the particular disease, condition or disorder, (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition or disorder described herein.
  • the therapeutically effective amount will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgement of the attending medical or veterinary practitioner, and other factors.
  • treating includes (1) preventing the disease state, i.e. causing the clinical symptoms of the disease state not to develop in a subject that may be exposed to or predisposed to the disease state, but does not yet experience or display symptoms of the disease state, (2) inhibiting the disease state, i.e., arresting the development of the disease state or its clinical symptoms, or (3) relieving the disease state, i.e., causing temporary or permanent regression of the disease state or its clinical symptoms.
  • Appropriate coupling agents are carbodiimides or uronium salts, such as for example N,N′-carbonyldiimidazole (CDI), N,N′-dicyclohexylcarbodiimide (DCC), N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide-hydrochloride (EDCI), O-(benzotriazol-1-yl)-N,N,N,N-tetramethyluronium tetrafluoroborate (TBTU) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU).
  • CDI N,N′-carbonyldiimidazole
  • DCC N,N′-dicyclohexylcarbodiimide
  • EDCI N-(3-dimethylaminopropyl)
  • the term “under basic conditions” means the presence of a base, particularly an alkylamine such as diisopropylethylamine (DIEA) or triethylamine (TEA), or a tertiary amine such as N-methylmorpholine or 4-(dimethylamino)-pyridine.
  • a base particularly an alkylamine such as diisopropylethylamine (DIEA) or triethylamine (TEA), or a tertiary amine such as N-methylmorpholine or 4-(dimethylamino)-pyridine.
  • DIEA diisopropylethylamine
  • TEA triethylamine
  • a tertiary amine such as N-methylmorpholine or 4-(dimethylamino)-pyridine.
  • DMF N,N-dimethylformamide
  • DMAc dimethylacetamide
  • Particular mineral acids for the deprotection are sulfuric acid or hydrochloric acid, more particularly hydrochloric acid in a solvent such as an ether, particularly diethyl ether or 1,4-dioxane, or neat trifluoroacetic acid.
  • Sulfinyl imines of general formula A can be prepared in analogy to T. P. Tang & J. A. Ellman, J. Org. Chem. 1999, 64, 12, by condensation of an aryl ketone and a sulfinamide, e.g. an alkyl sulfinamide, most particularly (R)-(+)-tert-butylsulfinamide in the presence of a Lewis acid such as e.g. a titanium(IV)alkoxyde, more particularly titanium(IV)ethoxide in a solvent such as an ether, e.g. diethyl ether or more particularly THF.
  • a Lewis acid such as e.g. a titanium(IV)alkoxyde, more particularly titanium(IV)ethoxide
  • a solvent such as an ether, e.g. diethyl ether or more particularly THF.
  • the conversion of the sulfinyl imine A to the sulfinamide ester B or Ba proceeds stereoselectively by the chiral directing group as described by Tang & Ellman.
  • the sulfinyl imine A can be reacted with a titanium enolate generated from e.g. an alkyl acetate, particularly methyl acetate, LDA and chlorotriisopropoxytitanium at low temperature, particularly at ⁇ 78° C. in a solvent such as an ether, e.g. diethyl ether or more particularly THF.
  • Hydrolysis of the chiral directing group in the sulfinamide ester B to give the amino ester C can be accomplished with a mineral acid, e.g. sulfuric acid or particularly hydrochloric acid in a solvent such as an ether, e.g. diethyl ether or more particularly 1,4-dioxane.
  • a mineral acid e.g. sulfuric acid or particularly hydrochloric acid
  • a solvent such as an ether, e.g. diethyl ether or more particularly 1,4-dioxane.
  • Aminoalcohol D can be prepared by the reduction of the methylester with an alkali hydride, particularly lithium borohydride or lithium aluminium hydride in a solvent such as an ether, e.g. diethyl ether or more particularly THF.
  • an alkali hydride particularly lithium borohydride or lithium aluminium hydride
  • a solvent such as an ether, e.g. diethyl ether or more particularly THF.
  • Aminooxazine E can be prepared by a two-step procedure involving first the reaction of amino alcohol D and cyanogenbromide in a solvent such as an ether, particularly THF, followed by reaction with a mineral acid, particularly hydrochloric acid in a solvent such as THF.
  • Boc-protected Aminooxazine F can be prepared by reaction of aminooxazine with di-tert-butyl-dicarbonate with an alkylamine such as TEA or particularly diisopropylamine in a solvent such as an ether, particularly THF.
  • the reduction of the nitro group in the Boc-protected Aminooxazine F to the aniline G can be accomplished by hydrogenation using a catalysts such as Pd/C in protic solvents, such as alcohols, preferably ethanol or methanol.
  • Amide coupling of the aniline G and a carboxylic acid to give the amide H can be effected with a carbodiimide, e.g. DCC or EDCI in a solvent such as dichloromethane.
  • a carbodiimide e.g. DCC or EDCI
  • a solvent such as dichloromethane.
  • Deprotection of the tert-butyloxycarbonyl group in H is effected with trifluoroacetic acid in a solvent such as dichloromethane.
  • hydrolysis of the chiral directing group and the t-butyl ester in the sulfinamide ester Ba to give the amino acid Ca can be accomplished with a mineral acid, e.g. sulfuric acid or particularly hydrochloric acid in a solvent such as an ether, e.g. diethyl ether or 1,4-dioxane or an ester e.g. methyl acetate or more particularly ethyl acetate.
  • a mineral acid e.g. sulfuric acid or particularly hydrochloric acid
  • a solvent such as an ether, e.g. diethyl ether or 1,4-dioxane or an ester e.g. methyl acetate or more particularly ethyl acetate.
  • the reduction of the amino acid Ca to give the amino alcohol Da can be effected with an alkali hydride, e.g. lithium borohydride or lithium aluminium hydride or a borane, preferably BH 3 -THF complex in an ether as solvent, e.g. diethyl ether or more particularly THF.
  • an alkali hydride e.g. lithium borohydride or lithium aluminium hydride or a borane, preferably BH 3 -THF complex in an ether as solvent, e.g. diethyl ether or more particularly THF.
  • Ring closure of the amino alcohol Da to give the amino oxazine Ea can be prepared by a two-step procedure involving first the reaction of the amino alcohol Da and cyanogenbromide in a solvent such as an ether, particularly THF, followed by reaction with a mineral acid, particularly hydrochloric acid in a solvent such as THF.
  • the reduction of the nitro group in the intermediate Ea to give the aniline Fa can be accomplished by hydrogenation using a catalyst such as Pd/C in protic solvents, such as alcohols, particularly methanol or more particularly ethanol.
  • aminooxazines K can be prepared from an amino alcohol such as Jb (preparation described in WO 2009091016) by a two-step procedure involving first the reaction of amino alcohol J and cyanogenbromide in a solvent such as an ether, particularly THF, followed by reaction with a mineral acid, particularly hydrochloric acid in a solvent such as THF.
  • a solvent such as an ether, particularly THF
  • the reduction of the nitro group in aminooxazine Eb to the aniline Fb can be accomplished by hydrogenation using a catalyst such as Pd/C in protic solvents, such as alcohols, particularly methanol or more particularly ethanol.
  • a catalyst such as Pd/C in protic solvents, such as alcohols, particularly methanol or more particularly ethanol.
  • Amide coupling of the aniline Fb and a carboxylic acid to give the amides I can be effected with a carbodiimide, e.g. DCC, EDCI or preferably DMTMM in a suitable solvent such as methanol.
  • a carbodiimide e.g. DCC, EDCI or preferably DMTMM in a suitable solvent such as methanol.
  • the compounds of formula I of the present invention can be used as medicaments for the treatment of diseases which are associated with the inhibition of BACE2.
  • the compounds of formula I of the present invention can be used as medicaments for the treatment of diseases which are associated with the inhibition of BACE2.
  • the compounds of formula I of the invention will be useful in preserving and restoring beta-cell function and stimulating insulin secretion in diabetic patients and in non-diabetic patients who have impaired glucose tolerance or who are in a pre-diabetic condition. They may be useful in treating type 1 diabetes or in delaying or preventing a patient with type 2 diabetes from needing insulin therapy.
  • the compounds of formula I are further useful to ameliorate hyperinsulinemia, which often occurs in diabetic or pre-diabetic patients and in reducing the risks associated with metabolic syndrome, they may also be useful in treating vascular diseases such as hypertension.
  • the expression ‘diseases which are associated with the inhibition of BACE2 activity’ means diseases such as metabolic and cardiovascular diseases, in particular diabetes, more particularly type 2 diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, pre-diabetes, metabolic syndrome, diabetes type 1, complications of diabetes including diabetic nephropathy, diabetic retinopathy and diabetic neuropathy, chronic kidney disease, dyslipidemia, atherosclerosis, myocardial infarction, hypertension and further metabolic and cardiovascular disorders.
  • diseases such as metabolic and cardiovascular diseases, in particular diabetes, more particularly type 2 diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, pre-diabetes, metabolic syndrome, diabetes type 1, complications of diabetes including diabetic nephropathy, diabetic retinopathy and diabetic neuropathy, chronic kidney disease, dyslipidemia, atherosclerosis, myocardial infarction, hypertension and further metabolic and cardiovascular disorders.
  • the expression ‘diseases which are associated with the inhibition of BACE2 activity’ relates to diabetes, particularly type II diabetes, impaired glucose tolerance, pre-diabetes, metabolic syndrome and hypertension. More particularly, the expression ‘diseases which are associated with the inhibition of BACE2 activity’ relates to diabetes, most particularly type 2 diabetes.
  • the invention also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant. More specifically, the invention relates to pharmaceutical compositions useful for the treatment of diseases which are associated with the inhibition of BACE2 activity.
  • the invention relates to compounds of formula I as defined above for use as medicaments, particularly as medicaments for the treatment or prevention of diseases which are associated with the inhibition of BACE2 activity.
  • compounds of formula I for use in diabetes particularly type 2 diabetes.
  • the invention relates to a method for the treatment or prevention of diseases which are associated with the inhibition of BACE2 activity, which method comprises administering a therapeutically active amount of a compound of formula Ito a human being or animal.
  • the invention further relates to the use of compounds of formula I as defined above for the treatment of diseases which are associated with the inhibition of BACE2 activity.
  • the invention relates to the use of compounds of formula I as defined above for the preparation of medicaments for the treatment or prevention of diseases which are associated with the inhibition of BACE2 activity.
  • the compounds of formula I and their pharmaceutically acceptable salts can be used as medicaments, e.g., in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g., in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g., in the form of suppositories, parenterally, e.g., in the form of injection solutions or suspensions or infusion solutions, or topically, e.g., in the form of ointments, creams or oils. Oral administration is particular.
  • the production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials.
  • lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragées and hard gelatine capsules.
  • Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules).
  • Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like.
  • Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils.
  • Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols.
  • Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
  • Usual stabilizers preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
  • the dosage of the compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 1000 mg, especially about 1 to 300 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g., in 1 to 3 dosage units.
  • the pharmaceutical preparations conveniently contain about 1-500 mg, particularly 1-100 mg, of a compound of formula I.
  • DCC N,N′-diisopropyl-carbodiimide
  • DIEA diisopropylethylamine
  • DMAc dimethylacetamide
  • DMAP 4-dimethylaminopyridine
  • DMF N,N-dimethylformamide
  • DMSO dimethyl sulfoxide
  • EDCI N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide hydrochloride
  • HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate
  • HCl hydrogen chloride
  • HPLC high performance liquid chromatography
  • LDA lithium diisopropylamide
  • MS mass spectrum
  • NMR nuclear magnetic resonance
  • TEA triethylamine
  • THF tetrahydrofuran.
  • the assay uses the principle of inhibition of human TMEM27 cleavage by endogenous cellular BACE2 in the Ins1e rat cell line and shedding from the cell surface into the culture medium, followed by detection in an ELISA assay. Inhibition of BACE2 prevents the cleavage and shedding in a dose-dependent manner.
  • the stable cell line “INS-TMEM27” represents an INS1e-derived cell line with inducible expression (using the TetOn system) of full-length hTMEM27 in a doxycycline-dependent manner.
  • the cells were cultured throughout the experiment in RPMI1640+Glutamax (Invitrogen) Penicillin/Streptomycin, 10% Fetal bovine serum, 100 mM pyruvate, 5 mM beta-mercaptoethanol, 100 micrograms/ml G418 and 100 microgram/ml hygromycin and were grown in adherent culture at 37° C. in a standard CO 2 cell culture incubator.
  • INS-TMEM27 cells were seeded in 96-well plates. After 2 days in culture, BACE2 inhibitor was added in a range of concentrations as required by the assay and after a further two hours, doxycycline was added to a final concentration of 500 ng/ml. The cells were incubated for a further 46 hours and the supernatant harvested for detection of shed TMEM27.
  • An ELISA assay (using a pair of mouse anti-human-TMEM27 antibodies, raised against the extracellular domain of TMEM27) was used for detection of TMEM27 in the culture medium.
  • An IC 50 for BACE2 inhibition was calculated using the ELISA readout for each inhibitor concentration with standard curve-fitting software XLfit (IDBS) for the Excel spreadsheet program.
  • the particular compounds according to formula I have an inhibitory activity in the above assay (IC 50 ) particularly of 5 nM to 50 ⁇ M, more particularly of 5 nM to 1 ⁇ M.
  • Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
  • Kernel Compound of formula I 10.0 mg 200.0 mg Microcrystalline cellulose 23.5 mg 43.5 mg Lactose hydrous 60.0 mg 70.0 mg Povidone K30 12.5 mg 15.0 mg Sodium starch glycolate 12.5 mg 17.0 mg Magnesium stearate 1.5 mg 4.5 mg (Kernel Weight) 120.0 mg 350.0 mg Film Coat: Hydroxypropyl methyl cellulose 3.5 mg 7.0 mg Polyethylene glycol 6000 0.8 mg 1.6 mg Talc 1.3 mg 2.6 mg Iron oxyde (yellow) 0.8 mg 1.6 mg Titan dioxide 0.8 mg 1.6 mg
  • the active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water.
  • the granulate is mixed with sodium starch glycolate and magnesiumstearate and compressed to yield kernels of 120 or 350 mg respectively.
  • the kernels are lacquered with an aqueous solution/suspension of the above mentioned film coat.
  • Capsules containing the following ingredients can be manufactured in a conventional manner:
  • the components are sieved and mixed and filled into capsules of size 2.
  • Injection solutions can have the following composition:
  • the active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part).
  • the pH is adjusted to 5.0 by Acetic Acid.
  • the volume is adjusted to 1.0 ml by addition of the residual amount of water.
  • the solution is filtered, filled into vials using an appropriate overage and sterilized.
  • Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
  • Capsule contents Compound of formula I 5.0 mg Yellow wax 8.0 mg Hydrogenated Soya bean oil 8.0 mg Partially hydrogenated plant oils 34.0 mg Soya bean oil 110.0 mg Weight of capsule contents 165.0 mg Gelatin capsule Gelatin 75.0 mg Glycerol 85% 32.0 mg Karion 83 8.0 mg (dry matter) Titan dioxide 0.4 mg Iron oxide yellow 1.1 mg
  • the active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size.
  • the filled soft gelatin capsules are treated according to the usual procedures.
  • Sachets containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water.
  • the granulate is mixed with magnesium stearate and the flavouring additives and filled into sachets.

Abstract

This invention relates to 5,6-dihydro-4H-[1,3]oxazin-2-ylamine compounds of the formula
Figure US20110144098A1-20110616-C00001
wherein R1 to R5 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the treatment or prevention of diseases such as diabetes.

Description

    PRIORITY TO RELATED APPLICATION(S)
  • This application claims the benefit of European Patent Application No. 09178642.6 filed Dec. 10, 2009, which is hereby incorporated by reference in its entirety.
    • FIELD OF THE INVENTION
  • The present invention relates to compounds useful in the treatment of type 2 diabetes and other metabolic disorders.
    • BACKGROUND
  • Type 2 diabetes (T2D) is caused by insulin resistance and inadequate insulin secretion from pancreatic beta-cells leading to poor blood-glucose control and hyperglycemia (M Prentki & C J Nolan, “Islet beta-cell failure in type 2 diabetes.” J. Clin. Investig. 2006, 116(7), 1802-1812). Patients with T2D have an increased risk of microvascular and macrovascular disease and a range of related complications including diabetic nephropathy, retinopathy and cardiovascular disease. In 2000 an estimated 171 million people had the condition with the expectation that this figure will double by 2030 (S Wild, G Roglic, A Green, R. Sicree & H King, “Global prevalence of diabetes”, Diabetes Care 2004, 27(5), 1047-1053) making the disease a major healthcare problem. The rise in prevalence of T2D is associated with an increasingly sedentary lifestyle and high-energy food intake of the world's population (P Zimmet, K G M M Alberti & J Shaw, “Global and societal implications of the diabetes epidemic” Nature 2001, 414, 782-787).
  • Beta-cell failure and consequent dramatic decline in insulin secretion and hyperglycemia marks the onset of T2D (M Prentki & C J Nolan, “Islet beta-cell failure in type 2 diabetes.” J. Clin. Investig. 2006, 116(7), 1802-1812). Most current treatments do not prevent the loss of beta-cell mass characterising overt T2D. However, recent developments with GLP-1 analogues, gastrin and other agents show that preservation and proliferation of beta-cells is possible to achieve, leading to an improved glucose tolerance and slower progression to overt T2D (L L Baggio & D J Drucker, “Therapeutic approaches to preserve islet mass in type 2 diabetes”, Annu Rev. Med. 2006, 57, 265-281).
  • Tmem27 has been identified as a protein promoting beta-cell proliferation (P Akpinar, S Kuwajima, J Kriitzfeldt, M Stoffel, “Tmem27: A cleaved and shed plasma membrane protein that stimulates pancreatic (3 cell proliferation”, Cell Metab. 2005, 2, 385-397) and insulin secretion (K Fukui, Q Yang, Y Cao, N Takahashi et al., “The HNF-1 target Collectrin controls insulin exocytosis by SNARE complex formation”, Cell Metab. 2005, 2, 373-384). Tmem27 is a 42 kDa membrane glycoprotein which is constitutively shed from the surface of beta-cells, resulting from a degradation of the full-length cellular Tmem27. Overexpression of Tmem27 in a transgenic mouse increases beta-cell mass and improves glucose tolerance in a DIO model of diabetes [K Fukui, Q Yang, Y Cao, N Takahashi et al., “The HNF-1 target Collectrin controls insulin exocytosis by SNARE complex formation”, Cell Metab. 2005, 2, 373-384, P Akpinar, S Kuwajima, J Kriitzfeldt, M Stoffel, “Tmem27: A cleaved and shed plasma membrane protein that stimulates pancreatic β cell proliferation”, Cell Metab. 2005, 2, 385-397). Furthermore, siRNA knockout of Tmem27 in a rodent beta-cell proliferation assay (eg using INS1e cells) reduces the proliferation rate, indicating a role for Tmem27 in control of beta-cell mass.
  • In vitro, BACE2 cleaves a peptide based on the sequence of Tmem27. The closely related protease BACE1 does not cleave this peptide and selective inhibition of BACE1 alone does not enhance proliferation of beta-cells. BACE1 (BACE for beta-site APP-cleaving enzyme, also known as beta-secretase) has been implicated in the pathogenesis of Alzheimer disease and in the formation of myelin sheaths in peripheral nerve cells.
  • The close homolog BACE2 is a membrane-bound aspartyl protease and is colocalised with Tmem27 in rodent pancreatic beta-cells (G Finzi, F Franzi, C Placidi, F Acquati et al., “BACE2 is stored in secretory granules of mouse and rat pancreatic beta cells”, Ultrastruct Pathol. 2008, 32(6), 246-251). It is also known to be capable of degrading APP (I Hussain, D Powell, D Howlett, G Chapman et al., “ASP1 (BACE2) cleaves the amyloid precursor protein at the β-secretase site” Mol Cell Neurosci. 2000, 16, 609-619), IL-1R2 (P Kuhn, E Marjaux, A Imhof, B De Strooper et al., “Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase” J. Biol. Chem. 2007, 282(16), 11982-11995).
  • Inhibition of BACE2 is therefore proposed as a treatment for type 2 diabetes with the potential to preserve and restore beta-cell mass and stimulate insulin secretion in pre-diabetic and diabetic patients. It is therefore an object of the present invention to provide selective BACE2 inhibitors. Such compounds are useful as therapeutically active substances, particularly in the treatment and/or prevention of diseases which are associated with the inhibition of BACE2.
  • The compounds of the present invention exceed the compounds known in the art, inasmuch as they are strong and selective inhibitors of BACE2. They are expected to have an enhanced therapeutic potential compared to the compounds already known in the art and can be used for the treatment and prevention of diabetes, particularly type 2 diabetes, metabolic syndrome and a wide range of metabolic disorders.
    • SUMMARY
  • The present invention relates to compounds of formula I,
  • Figure US20110144098A1-20110616-C00002
  • wherein
    • R1 is hydrogen or C1-7-alkyl;
    • R2 is hydrogen or C1-7-alkyl;
    • or R1 and R2 together with the C atom they are attached to form a C3-7-cycloalkyl ring;
    • R3 is C1-7-alkyl or C3-7-cycloalkyl;
      • or R2 and R3 together with the C atoms they are attached to form a C3-7-cycloalkyl or a 3- to 7-membered O-heterocyclyl ring;
    • R4 is selected from the group consisting of hydrogen, C1-7-alkyl, halogen, cyano and C1-7-alkoxy; and
    • R5 is selected from the group consisting of:
      • i) aryl, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl,
      • ii) heteroaryl, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl,
      • iii) C1-7-alkyl, unsubstituted or substituted by one, two, three, four or five groups individually selected from the group consisting of halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano and hydroxy-C1-7-alkyl,
      • iv) a C3-7-cycloalkyl ring, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano and hydroxy-C1-7-alkyl, and
      • v) 3- to 7-membered O-heterocyclyl ring, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano and hydroxy-C1-7-alkyl,
        or pharmaceutically acceptable salts thereof.
  • The invention is also concerned with the manufacture of compounds of formula I, with pharmaceutical compositions containing them and their use as medicaments. The compounds of formula I are inhibitors of BACE2 and may therefore be useful in the treatment of type 2 diabetes and other metabolic disorders.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described below.
  • All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.
  • The nomenclature used in this Application is based on IUPAC systematic nomenclature, unless indicated otherwise.
  • Unless otherwise indicated, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention.
  • The term “compound(s) of this invention” and “compound(s) of the present invention” refers to compounds of formula I and stereoisomers, tautomers, solvates, and salts (e.g., pharmaceutically acceptable salts) thereof.
  • Structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example wherein one or more hydrogen atoms are replaced by deuterium, or one or more carbon atoms are replaced by a 13C- or 14C-enriched carbon are within the scope of this invention.
  • The term “halogen” refers to fluorine (fluoro, F), chlorine (chloro, Cl), bromine (bromo, Br) and iodine (iodo, I), with fluorine, chlorine and bromine being particular, and with fluorine and chlorine being more particular. Most particular is F.
  • The term “lower alkyl” or “C1-7-alkyl”, alone or in combination, signifies a straight-chain or branched-chain alkyl group with 1 to 7 carbon atoms, particularly a straight or branched-chain alkyl group with 1 to 6 carbon atoms and particularly particular a straight or branched-chain alkyl group with 1 to 4 carbon atoms. Examples of straight-chain and branched C1-7 alkyl groups are methyl (Me), ethyl (Et), propyl, isopropyl, butyl, isobutyl, tert.-butyl, the isomeric pentyls, the isomeric hexyls and the isomeric heptyls, particularly methyl and ethyl and most particular methyl.
  • The term “lower alkoxy” or “C1-7-alkoxy” refers to the group R′—O—, wherein R′ is lower alkyl and the term “lower alkyl” has the previously given significance. Examples of lower alkoxy groups are methoxy (MeO, OMe), ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy and tert.-butoxy, particularly methoxy and ethoxy.
  • The term “lower halogenalkyl” or “halogen-C1-7-alkyl” refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a halogen atom, particularly fluoro or chloro, most particularly fluoro. Among the particular lower halogenalkyl groups are trifluoromethyl, difluoromethyl, trifluoroethyl, 2,2-difluoroethyl, fluoromethyl and chloromethyl, with trifluoromethyl or difluoromethyl being especially particular.
  • The term “lower halogenalkoxy” or “halogen-C1-7-alkoxy” refers to lower alkoxy groups as defined above wherein at least one of the hydrogen atoms of the lower alkoxy group is replaced by a halogen atom, particularly fluoro or chloro, most particularly fluoro. Among the particular halogenated lower alkoxy groups are trifluoromethoxy, difluoromethoxy, fluormethoxy and chloromethoxy, with trifluoromethoxy being especially particular.
  • The term “lower hydroxyalkyl” or “hydroxy-C1-7-alkyl” refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a hydroxy group. Among the particular lower hydroxyalkyl groups are hydroxymethyl or hydroxyethyl.
  • The term “oxo” means the group “═O” bound to a ring atom.
  • The term “cycloalkyl” or “C3-7-cycloalkyl” denotes a saturated carbocyclic group containing from 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Especially particular are cyclopropyl, cyclobutyl and cyclopentyl. Specific is cyclopropyl.
  • The term “3- to 7-membered O-heterocyclyl ring” denotes a saturated 3- to 7-membered heterocyclyl ring containing at least one oxygen atom, such as oxirane, oxetane, tetrahydrofurane, tetrahydropurane and oxepane. A tetrahydrofurane (furyl) ring is particular. Specific is oxetanyl.
  • The term “aryl” refers to an aromatic monocyclic or multicyclic ring system having 6 to 14 carbon atoms, particularly 6 to 10 carbon atoms. Particular aryl groups are phenyl and naphthyl, with phenyl being most particular.
  • The term “heteroaryl” refers to an aromatic or partly unsaturated 5- or 6-membered ring which comprises at least one heteroatom selected from nitrogen, oxygen and/or sulphur, and can in addition comprise one or three atoms selected from nitrogen, oxygen and/or sulphur, such as pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 6-oxo-1,6-dihydropyridazinyl, 5-oxo-4,5-dihydropyrazinyl, pyrrolyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyrazolyl, imidazolyl, triazolyl and thiazolyl. The term “heteroaryl” further refers to bicyclic aromatic or partly unsaturated groups comprising two 5- or 6-membered rings, in which one or both rings can contain one, two or three atoms selected from nitrogen, oxygen or sulphur, such as quinolinyl, isoquinolinyl, cinnolinyl, pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, thieno[2,3-c]pyridyl, quinoxalinyl, benzo[b]thienyl, benzothiazolyl, benzotriazolyl, indolyl, indazolyl and 3,4-dihydro-1H-isoquinolinyl. Particular heteroaryl groups are thienyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, 6-oxo-1,6-dihydropyridazinyl, 5-oxo-4,5-dihydropyrazinyl and imidazo[1,2-a]pyridyl, with thienyl, oxazolyl, pyrazolyl, pyridyl, pyrimidinyl and pyrazinyl being more particular and pyridyl being most particular. Specific are 1H-pyrazolyl, benzo[b]thiophenyl, isoxazolyl, oxazolyl, pyrazinyl, pyridinyl, pyrimidinyl, thiazolyl, thieno[2,3-c]pyridinyl and thiophenyl, more specific are 1H-pyrazole-3-yl, benzo[b]thiophene-2-yl, isoxazole-3-yl, oxazole-4-yl, pyrazine-2-yl, pyridine-2-yl, pyrimidine-2-yl, thiazol-4-yl, thieno[2,3-c]pyridine-7-yl and thiophene-2-yl.
  • Compounds of formula I can form pharmaceutically acceptable salts. The term “pharmaceutically acceptable salts” refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. Particularly, the pharmaceutically acceptable salts of the compounds of formula I are the acid addition salts with physiologically compatible mineral acids, such as hydrochloric acid, sulfuric acid, sulfurous acid or phosphoric acid; or with organic acids, such as methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxylic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, malonic acid, tartaric acid, benzoic acid, cinnamic acid, mandelic acid, succinic acid or salicylic acid. Particularly particular pharmaceutically acceptable salts of compounds of formula I are the acid addition salts such as the hydrochloride salts, the formate salts or trifluoroacetate salts.
  • The compounds of formula I can also be solvated, e.g., hydrated. The solvation can be effected in the course of the manufacturing process or can take place e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of formula I (hydration). The term “pharmaceutically acceptable salts” also includes physiologically acceptable solvates.
  • “Isomers” are compounds that have identical molecular formulae but that differ in the nature or the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereoisomers”, and stereoisomers that are non-superimposable mirror images are termed “enantiomers”, or sometimes optical isomers. A carbon atom bonded to four non-identical substituents is termed a “chiral center”. The term “chiral” denotes the ability of non-superimposability with the mirror image, while the term “achiral” refers to embodiments which are superimposable with their mirror image. Chiral molecules are optically active, i.e., they have the ability to rotate the plane of plane-polarized light. Compounds of present invention can have one or more chiral centers and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. Whenever a chiral center is present in a chemical structure, it is intended that all stereoisomers associated with that chiral center are encompassed by the present invention.
  • In detail, the invention relates to compounds of formula I,
  • Figure US20110144098A1-20110616-C00003
  • wherein
    • R1 is hydrogen or C1-7-alkyl;
    • R2 is hydrogen or C1-7-alkyl;
    • or R1 and R2 together with the C atom they are attached to form a C3-7-cycloalkyl ring;
    • R3 is C1-7-alkyl or C3-7-cycloalkyl;
      • or R2 and R3 together with the C atoms they are attached to form a C3-7-cycloalkyl or a 3- to 7-membered O-heterocyclyl ring;
    • R4 is selected from the group consisting of hydrogen, C1-7-alkyl, halogen, cyano and C1-7-alkoxy; and
    • R5 is selected from the group consisting of:
      • i) aryl, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl,
      • ii) heteroaryl, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl,
      • iii) C1-7-alkyl, unsubstituted or substituted by one, two, three, four or five groups individually selected from the group consisting of halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano and hydroxy-C1-7-alkyl,
      • iv) a C3-7-cycloalkyl ring, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano and hydroxy-C1-7-alkyl, and
      • v) 3- to 7-membered O-heterocyclyl ring, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano and hydroxy-C1-7-alkyl,
        or pharmaceutically acceptable salts thereof.
  • In a particular embodiment, the invention relates to compounds of formula I, wherein
    • R1 is hydrogen or C1-7-alkyl;
    • R2 is hydrogen or C1-7-alkyl;
      • or R1 and R2 together with the C atom they are attached to form a C3-7-cycloalkyl ring;
    • R3 is C1-7-alkyl or C3-7-cycloalkyl;
      • or R2 and R3 together with the C atoms they are attached to form a C3-7-cycloalkyl or a 3- to 7-membered O-heterocyclyl ring;
    • R4 is selected from the group consisting of hydrogen, C1-7-alkyl, halogen, cyano and C1-7-alkoxy; and
    • R5 is aryl or heteroaryl, said aryl or heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl;
      or pharmaceutically acceptable salts thereof.
  • In a particular embodiment, the invention relates to compounds of formula I, wherein
    • R1 is hydrogen;
    • R2 is hydrogen;
    • R3 is C1-7-alkyl;
    • R4 is halogen; and
    • R5 is selected from the group consisting of 1H-pyrazolyl, benzo[b]thiophenyl, isoxazolyl, oxazolyl, pyrazinyl, pyridinyl, pyrimidinyl, thiazolyl, thieno[2,3-c]pyridinyl, thiophenyl, phenyl, ethyl, cyclopropyl and oxetanyl being unsubstituted or substituted as defined herein;
      or pharmaceutically acceptable salts thereof.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R1 and R2 together with the C atom they are attached to form a C3-7-cycloalkyl ring.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R2 and R3 together with the C atom they are attached to form a C3-7-cycloalkyl ring.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R2 and R3 together with the C atom they are attached to form furyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R1 and R2 together with the C atom they are attached to form a cyclopropyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R1 and R2 are each hydrogen.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R1 is hydrogen.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R2 is hydrogen.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R3 is C1-7-alkyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R3 is methyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R3 is ethyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R4 is hydrogen or halogen.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R4 is halogen.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R4 is fluoro.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is heteroaryl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is heteroaryl selected from the group consisting of pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 6-oxo-1,6-dihydropyridazinyl, 5-oxo-4,5-dihydropyrazinyl, pyrrolyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, thieno[2,3-c]pyridyl, quinoxalinyl, benzo[b]thienyl, benzothiazolyl, benzotriazolyl, indolyl, indazolyl and 3,4-dihydro-1H-isoquinolinyl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is heteroaryl selected from the group consisting of thienyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, 6-oxo-1,6-dihydropyridazinyl, 5-oxo-4,5-dihydropyrazinyl and imidazo[1,2-a]pyridyl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is heteroaryl selected from the group consisting of thienyl, oxazolyl, pyridyl, pyrimidinyl and pyrazinyl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is heteroaryl selected from the group consisting of thienyl, oxazolyl, pyridyl, pyrimidinyl and pyrazinyl substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is heteroaryl selected from the group consisting of 1H-pyrazolyl, benzo[b]thiophenyl, isoxazolyl, oxazolyl, pyrazinyl, pyridinyl, pyrimidinyl, thiazolyl, thieno[2,3-c]pyridinyl and thiophenyl, said heteroaryl being unsubstituted or substituted by one or two groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkoxy, halogen-C1-7-alkyl, C1-7-alkoxy, cyano and phenyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is heteroaryl selected from the group consisting of 1H-pyrazolyl, thiazolyl, oxazolyl, pyridinyl, substituted by one or two substituents selected from the group consisting of C1-7-alkyl, halogen and cyano.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is 1H-pyrazolyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is thiazolyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is oxazolyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is pyridinyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is heteroaryl selected from the group consisting of 1H-pyrazole-3-yl, benzo[b]thiophene-2-yl, isoxazole-3-yl, oxazole-4-yl, pyrazine-2-yl, pyridine-2-yl, pyrimidine-2-yl, thiazol-4-yl, thieno[2,3-c]pyridine-7-yl and thiophene-2-yl, said heteroaryl being unsubstituted or substituted by one or two groups selected from the group consisting of methyl, fluoro, chloro, difluoromethoxy, trifluoroethoxy, trifluoromethyl, methoxy, cyano and phenyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is phenyl, said phenyl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is phenyl, substituted by one or two halogens.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is C1-7-alkyl, unsubstituted or substituted by one, two, three, four or five halogens.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is ethyl, substituted by one, two, three, four or five fluoros.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is C3-7-cycloalkyl ring, unsubstituted or substituted by one, two or three groups selected from the group consisting of halogen and halogen-C1-7-alkyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is cyclopropyl, by one or two groups selected from the group consisting of fluoro and trifluoromethyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is 3- to 7-membered O-heterocyclyl ring, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano and hydroxy-C1-7-alkyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, wherein R5 is oxetanyl, substituted by methyl.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, selected from the group consisting of
    • 3,5-Dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • Pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Fluoro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 2-Methyl-oxazole-4-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 4-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • Thieno[2,3-c]pyridine-7-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Phenyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • Benzo[b]thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-pyrazine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • Pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3,5-Dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 2-Methyl-oxazole-4-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Cyano-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Methoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 2-Methyl-thiazole-4-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 1-Methyl-1H-pyrazole-3-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Methoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 6-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3,5-Difluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Chloro-5-fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • 3-Fluoro-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • 5-Methoxy-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-O-4-fluoro-phenyl]-amide,
    • 5-Fluoro-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • 5-Cyano-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • 5-Difluoromethoxy-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • Pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-pyrimidine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-O-4-fluoro-phenyl]-amide,
    • N-[3-((S)-2-Amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-2,3,3,3-tetrafluoro-propionamide,
    • 2,2-Difluoro-cyclopropanecarboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-2,6-difluorobenzamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-chloropicolinamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3,5-difluoropicolinamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-chloro-5-(trifluoromethyl)picolinamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-(trifluoromethyl)picolinamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-chloro-5-fluoropicolinamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3,5-dichloropicolinamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-1-(trifluoromethyl)cyclopropanecarboxamide,
    • N-(3-((S)-6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-2,2-difluorocyclopropanecarboxamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-4-chloro-1-methyl-1H-pyrazole-3-carboxamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-5-chloro-4-methylisoxazole-3-carboxamide,
    • 1-Trifluoromethyl-cyclopropanecarboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • N-[3-((S)-2-Amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-3,3,3-trifluoro-propionamide,
    • (S)-N-(3-(2-amino-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-3-(2,2,2-trifluoroethoxy)picolinamide,
    • 5-Difluoromethoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • (S)-N-(3-(2-amino-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-3-methyloxetane-3-carboxamide,
    • (S)-N-(3-(2-amino-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-4-methylisoxazole-3-carboxamide,
    • 4-Chloro-1H-pyrazole-3-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide, and
    • 5-Chloro-pyridine-2-carboxylic acid [3-((4aS,7aS)-2-amino-4a,5-dihydro-4H-furo[3,4-d][1,3]oxazin-7a-yl)-4-fluoro-phenyl]-amide,
      or pharmaceutically acceptable salts thereof.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, selected from the group consisting of
    • 3,5-Dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • Pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Fluoro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 2-Methyl-oxazole-4-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 4-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • Thieno[2,3-c]pyridine-7-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Phenyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • Benzo[b]thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-pyrazine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • Pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3,5-Dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 2-Methyl-oxazole-4-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Cyano-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Methoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 2-Methyl-thiazole-4-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 1-Methyl-1H-pyrazole-3-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Methoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 6-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3,5-Difluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-Chloro-5-fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • 3-Fluoro-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • 5-Methoxy-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-O-4-fluoro-phenyl]-amide,
    • 5-Fluoro-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • 5-Cyano-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • 5-Difluoromethoxy-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • Pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-pyrimidine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-O-4-fluoro-phenyl]-amide,
    • N-[3-((S)-2-Amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-2,3,3,3-tetrafluoro-propionamide,
    • 2,2-Difluoro-cyclopropanecarboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-2,6-difluorobenzamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-chloropicolinamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3,5-difluoropicolinamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-chloro-5-(trifluoromethyl)picolinamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-(trifluoromethyl)picolinamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-chloro-5-fluoropicolinamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3,5-dichloropicolinamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-1-(trifluoromethyl)cyclopropanecarboxamide,
    • N-(3-((S)-6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-2,2-difluorocyclopropanecarboxamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-4-chloro-1-methyl-1H-pyrazole-3-carboxamide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-5-chloro-4-methylisoxazole-3-carboxamide,
    • 1-Trifluoromethyl-cyclopropanecarboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • N-[3-((S)-2-Amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-3,3,3-trifluoro-propionamide,
    • (S)-N-(3-(2-amino-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-3-(2,2,2-trifluoroethoxy)picolinamide,
    • 5-Difluoromethoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • (S)-N-(3-(2-amino-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-3-methyloxetane-3-carboxamide,
    • (S)-N-(3-(2-amino-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-4-methylisoxazole-3-carboxamide, and
    • 4-Chloro-1H-pyrazole-3-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
      or pharmaceutically acceptable salts thereof.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, selected from the group consisting of
    • 3,5-Dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 2-Methyl-oxazole-4-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Cyano-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 2-Methyl-thiazole-4-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 1-Methyl-1H-pyrazole-3-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 6-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3,5-Difluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3,5-dichloropicolinamide, and
    • (S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-4-chloro-1-methyl-1H-pyrazole-3-carboxamide,
      or pharmaceutically acceptable salts thereof.
  • In a particular embodiment, the invention relates to compounds of formula I as herein described, selected from the group consisting of
    • 3,5-dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-fluoro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 2-methyl-oxazole-4-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 4-chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-chloro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • thieno[2,3-c]pyridine-7-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-phenyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • benzo[b]thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-chloro-pyrazine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide, pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-chloro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3,5-dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 2-methyl-oxazole-4-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-cyano-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-methoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 2-methyl-thiazole-4-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 1-methyl-1H-pyrazole-3-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-methoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 6-chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3,5-difluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3-chloro-5-fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
      or pharmaceutically acceptable salts thereof.
  • In a particular embodiment, the invention relates to a process of synthesizing compounds of formula I as herein described, which process comprises reacting an amine of the formula II
  • Figure US20110144098A1-20110616-C00004
  • wherein R1 to R4 are as defined herein and Boc is the protecting group tert-butyloxycarbonyl, with a carboxylic acid of the formula III
  • Figure US20110144098A1-20110616-C00005
  • wherein R5 is as defined herein, in the presence of a coupling reagent under basic conditions to obtain a compound of the formula IV
  • Figure US20110144098A1-20110616-C00006
  • and deprotecting the compound of formula IV with the help of a mineral acid to obtain the compound of formula I
  • Figure US20110144098A1-20110616-C00007
  • wherein R1 to R5 are as defined herein.
  • In a particular embodiment, the invention relates to pharmaceutical compositions comprising a compound of formula I as described herein and a pharmaceutically acceptable carrier and/or adjuvant.
  • In a particular embodiment, the invention relates to compounds of formula I as described herein for use as medicaments.
  • In a particular embodiment, the invention relates to compounds of formula I as described herein for use as medicaments for the treatment or prevention of diseases which are associated with inhibition of BACE2 activity.
  • In a particular embodiment, the invention relates to compounds of formula I as described herein for use as medicaments for the treatment or prevention of diabetes, particularly type 2 diabetes.
  • In a particular embodiment, the invention relates to compounds of formula I as described herein for use as medicaments for the treatment or prevention of type 2 diabetes.
  • In a particular embodiment, the invention relates to a method for the treatment of diseases which are associated with the inhibition of BACE 2 activity, particularly for the treatment of type 2 diabetes, which method comprises administering a therapeutically active amount of a compound of formula I as described herein to a human being or animal.
  • In a particular embodiment, the invention relates to the use of compounds of formula I as described herein for the preparation of medicaments for the treatment or prevention of diseases which are associated with the inhibition of BACE2 activity.
  • In a particular embodiment, the invention relates to the use of compounds of formula I as described herein for the preparation of medicaments for the treatment or prevention of diabetes, particularly type 2 diabetes.
  • Particularly, R3 signifies C1-7-alkyl. Compounds of formula I of the present invention are particular, wherein R3 is methyl or ethyl.
  • Another group of particular compounds are those, wherein or R2 and R3 together with the C atoms they are attached to form a C3-7-cycloalkyl or a 3- to 7-membered O-heterocyclyl ring, with those compounds being more particular, wherein R2 and R3 together with the C atoms they are attached to form a 3- to 7-membered O-heterocyclyl ring.
  • Furthermore, compounds of formula I according to the invention are particular, wherein R4 is hydrogen or halogen. More particularly, R4 is halogen. Especially particular are compounds of formula I, wherein R4 is hydrogen or fluoro, with those compounds of formula I, wherein R4 is fluoro being most particular.
  • In addition, compounds of formula I according to the present invention are particular, wherein R5 is heteroaryl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl.
  • Particularly particular compounds of formula I of the present invention are the following:
    • 3,5-dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3,5-dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 2-methyl-oxazole-4-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-cyano-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 5-chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 2-methyl-thiazole-4-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 1-methyl-1H-pyrazole-3-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 6-chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
    • 3,5-difluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
      or pharmaceutically acceptable salts thereof.
  • The pharmaceutically acceptable salts of the compounds of formula I also individually constitute particular compounds of the present invention.
  • Especially particular are the salts of compounds of formula I with HCl, formic acid and trifluoroacetic acid (CF3COOH), i.e. the chloride salts, the formate salts and trifluoroacetate salts.
  • The skilled person in the art will recognize that the compounds of formula I can exist in tautomeric forms, e.g. in the following tautomeric form:
  • Figure US20110144098A1-20110616-C00008
  • All tautomeric forms are encompassed in the present invention.
  • Compounds of formula I possess one asymmetric carbon atom and can exist in the form of optically pure enantiomers and mixtures of enantiomers such as, for example, racemates. The optically active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbens or eluant). The invention embraces all of these forms.
  • It will be appreciated, that the compounds of general formula I in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo. Physiologically acceptable and metabolically labile derivatives, which are capable of producing the parent compounds of general formula I in vivo are also within the scope of this invention.
  • The term “protecting group” denotes the group which selectively blocks a reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry. Protecting groups can be removed at the appropriate point. Exemplary protecting groups are amino-protecting groups, carboxy-protecting groups or hydroxy-protecting groups. The term “protecting group” in context with amines denotes groups intended to protect an amino group and includes benzyl, benzyloxycarbonyl (carbobenzyloxy, CBZ), Fmoc (9-Fluorenylmethyloxycarbonyl), p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, tert-butoxycarbonyl (BOC), and trifluoroacetyl. Further examples of these groups are found in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, 2nd ed., John Wiley & Sons, Inc., New York, N.Y., 1991, chapter 7; E. Haslam, “Protective Groups in Organic Chemistry”, J. G. W. McOmie, Ed., Plenum Press, New York, N.Y., 1973, Chapter 5, and T. W. Greene, “Protective Groups in Organic Synthesis”, John Wiley and Sons, New York, N.Y., 1981.
  • The term “half maximal inhibitory concentration” (IC50) denotes the concentration of a particular compound required for obtaining 50% inhibition of a biological process in vitro. IC50 values can be converted logarithmically to pIC50 values (−log IC50), in which higher values indicate exponentially greater potency. The IC50 value is not an absolute value but depends on experimental conditions e.g. concentrations employed. The IC50 value can be converted to an absolute inhibition constant (Ki) using the Cheng-Prusoff equation (Biochem. Pharmacol. (1973) 22:3099).
  • The term “inhibitor” denotes a compound which competes with, reduces or prevents the binding of a particular ligand to particular receptor or which reduces or prevents the inhibition of the function of a particular protein.
  • The term “therapeutically effective amount” denotes an amount of a compound of the present invention that, when administered to a subject, (i) treats or prevents the particular disease, condition or disorder, (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition or disorder described herein. The therapeutically effective amount will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgement of the attending medical or veterinary practitioner, and other factors.
  • The term “treating” or “treatment” of a disease state includes (1) preventing the disease state, i.e. causing the clinical symptoms of the disease state not to develop in a subject that may be exposed to or predisposed to the disease state, but does not yet experience or display symptoms of the disease state, (2) inhibiting the disease state, i.e., arresting the development of the disease state or its clinical symptoms, or (3) relieving the disease state, i.e., causing temporary or permanent regression of the disease state or its clinical symptoms.
  • Appropriate coupling agents are carbodiimides or uronium salts, such as for example N,N′-carbonyldiimidazole (CDI), N,N′-dicyclohexylcarbodiimide (DCC), N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide-hydrochloride (EDCI), O-(benzotriazol-1-yl)-N,N,N,N-tetramethyluronium tetrafluoroborate (TBTU) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU). The term “under basic conditions” means the presence of a base, particularly an alkylamine such as diisopropylethylamine (DIEA) or triethylamine (TEA), or a tertiary amine such as N-methylmorpholine or 4-(dimethylamino)-pyridine. The reaction is carried out in a suitable solvent such as for example N,N-dimethylformamide (DMF) or dimethylacetamide (DMAc), at temperatures between 0° C. and ambient temperature.
  • Particular mineral acids for the deprotection are sulfuric acid or hydrochloric acid, more particularly hydrochloric acid in a solvent such as an ether, particularly diethyl ether or 1,4-dioxane, or neat trifluoroacetic acid.
  • The invention further relates to compounds of formula I as defined above obtainable according to a process as defined above.
  • In more detail, compounds of formula I according to the present invention can be prepared by the methods and procedures given below. Typical procedures for the preparation of compounds of formula I is illustrated in Schemes 1 and 2.
  • Figure US20110144098A1-20110616-C00009
    Figure US20110144098A1-20110616-C00010
  • Figure US20110144098A1-20110616-C00011
  • Figure US20110144098A1-20110616-C00012
  • Sulfinyl imines of general formula A can be prepared in analogy to T. P. Tang & J. A. Ellman, J. Org. Chem. 1999, 64, 12, by condensation of an aryl ketone and a sulfinamide, e.g. an alkyl sulfinamide, most particularly (R)-(+)-tert-butylsulfinamide in the presence of a Lewis acid such as e.g. a titanium(IV)alkoxyde, more particularly titanium(IV)ethoxide in a solvent such as an ether, e.g. diethyl ether or more particularly THF.
  • The conversion of the sulfinyl imine A to the sulfinamide ester B or Ba proceeds stereoselectively by the chiral directing group as described by Tang & Ellman. The sulfinyl imine A can be reacted with a titanium enolate generated from e.g. an alkyl acetate, particularly methyl acetate, LDA and chlorotriisopropoxytitanium at low temperature, particularly at −78° C. in a solvent such as an ether, e.g. diethyl ether or more particularly THF.
  • Hydrolysis of the chiral directing group in the sulfinamide ester B to give the amino ester C can be accomplished with a mineral acid, e.g. sulfuric acid or particularly hydrochloric acid in a solvent such as an ether, e.g. diethyl ether or more particularly 1,4-dioxane.
  • Aminoalcohol D can be prepared by the reduction of the methylester with an alkali hydride, particularly lithium borohydride or lithium aluminium hydride in a solvent such as an ether, e.g. diethyl ether or more particularly THF.
  • Aminooxazine E can be prepared by a two-step procedure involving first the reaction of amino alcohol D and cyanogenbromide in a solvent such as an ether, particularly THF, followed by reaction with a mineral acid, particularly hydrochloric acid in a solvent such as THF.
  • Boc-protected Aminooxazine F can be prepared by reaction of aminooxazine with di-tert-butyl-dicarbonate with an alkylamine such as TEA or particularly diisopropylamine in a solvent such as an ether, particularly THF.
  • The reduction of the nitro group in the Boc-protected Aminooxazine F to the aniline G can be accomplished by hydrogenation using a catalysts such as Pd/C in protic solvents, such as alcohols, preferably ethanol or methanol.
  • Amide coupling of the aniline G and a carboxylic acid to give the amide H can be effected with a carbodiimide, e.g. DCC or EDCI in a solvent such as dichloromethane. Deprotection of the tert-butyloxycarbonyl group in H is effected with trifluoroacetic acid in a solvent such as dichloromethane.
  • Alternatively, hydrolysis of the chiral directing group and the t-butyl ester in the sulfinamide ester Ba to give the amino acid Ca can be accomplished with a mineral acid, e.g. sulfuric acid or particularly hydrochloric acid in a solvent such as an ether, e.g. diethyl ether or 1,4-dioxane or an ester e.g. methyl acetate or more particularly ethyl acetate.
  • The reduction of the amino acid Ca to give the amino alcohol Da can be effected with an alkali hydride, e.g. lithium borohydride or lithium aluminium hydride or a borane, preferably BH3-THF complex in an ether as solvent, e.g. diethyl ether or more particularly THF.
  • Ring closure of the amino alcohol Da to give the amino oxazine Ea can be prepared by a two-step procedure involving first the reaction of the amino alcohol Da and cyanogenbromide in a solvent such as an ether, particularly THF, followed by reaction with a mineral acid, particularly hydrochloric acid in a solvent such as THF.
  • The reduction of the nitro group in the intermediate Ea to give the aniline Fa can be accomplished by hydrogenation using a catalyst such as Pd/C in protic solvents, such as alcohols, particularly methanol or more particularly ethanol.
  • Coupling of the aniline Fa and a carboxylic acid to give the amide I was best accomplished with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride in a protic solvent such as an alcohol, particularly methanol.
  • Alternatively, aminooxazines K can be prepared from an amino alcohol such as Jb (preparation described in WO 2009091016) by a two-step procedure involving first the reaction of amino alcohol J and cyanogenbromide in a solvent such as an ether, particularly THF, followed by reaction with a mineral acid, particularly hydrochloric acid in a solvent such as THF.
  • Introduction of the nitro group in K to give Eb was best performed according to the standard procedure involving sulfuric acid and nitric acid at low temperature, preferably at 0° C.
  • The reduction of the nitro group in aminooxazine Eb to the aniline Fb can be accomplished by hydrogenation using a catalyst such as Pd/C in protic solvents, such as alcohols, particularly methanol or more particularly ethanol.
  • Amide coupling of the aniline Fb and a carboxylic acid to give the amides I can be effected with a carbodiimide, e.g. DCC, EDCI or preferably DMTMM in a suitable solvent such as methanol.
  • As described herein before, the compounds of formula I of the present invention can be used as medicaments for the treatment of diseases which are associated with the inhibition of BACE2.
  • As described herein before, the compounds of formula I of the present invention can be used as medicaments for the treatment of diseases which are associated with the inhibition of BACE2.
  • As described herein before, the compounds of formula I of the invention will be useful in preserving and restoring beta-cell function and stimulating insulin secretion in diabetic patients and in non-diabetic patients who have impaired glucose tolerance or who are in a pre-diabetic condition. They may be useful in treating type 1 diabetes or in delaying or preventing a patient with type 2 diabetes from needing insulin therapy. The compounds of formula I are further useful to ameliorate hyperinsulinemia, which often occurs in diabetic or pre-diabetic patients and in reducing the risks associated with metabolic syndrome, they may also be useful in treating vascular diseases such as hypertension.
  • Thus, the expression ‘diseases which are associated with the inhibition of BACE2 activity’ means diseases such as metabolic and cardiovascular diseases, in particular diabetes, more particularly type 2 diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, pre-diabetes, metabolic syndrome, diabetes type 1, complications of diabetes including diabetic nephropathy, diabetic retinopathy and diabetic neuropathy, chronic kidney disease, dyslipidemia, atherosclerosis, myocardial infarction, hypertension and further metabolic and cardiovascular disorders.
  • In a particular aspect, the expression ‘diseases which are associated with the inhibition of BACE2 activity’ relates to diabetes, particularly type II diabetes, impaired glucose tolerance, pre-diabetes, metabolic syndrome and hypertension. More particularly, the expression ‘diseases which are associated with the inhibition of BACE2 activity’ relates to diabetes, most particularly type 2 diabetes.
  • The invention also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant. More specifically, the invention relates to pharmaceutical compositions useful for the treatment of diseases which are associated with the inhibition of BACE2 activity.
  • Further, the invention relates to compounds of formula I as defined above for use as medicaments, particularly as medicaments for the treatment or prevention of diseases which are associated with the inhibition of BACE2 activity. Especially particular are compounds of formula I for use in diabetes, particularly type 2 diabetes.
  • In another aspect, the invention relates to a method for the treatment or prevention of diseases which are associated with the inhibition of BACE2 activity, which method comprises administering a therapeutically active amount of a compound of formula Ito a human being or animal. A method for the treatment of diabetes, particularly type 2 diabetes, is particular.
  • The invention further relates to the use of compounds of formula I as defined above for the treatment of diseases which are associated with the inhibition of BACE2 activity.
  • In addition, the invention relates to the use of compounds of formula I as defined above for the preparation of medicaments for the treatment or prevention of diseases which are associated with the inhibition of BACE2 activity. The use of compounds of formula I as defined above for the preparation of medicaments for the treatment or prevention of diabetes, particularly, type 2 diabetes, is especially particular.
  • The compounds of formula I and their pharmaceutically acceptable salts can be used as medicaments, e.g., in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g., in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g., in the form of suppositories, parenterally, e.g., in the form of injection solutions or suspensions or infusion solutions, or topically, e.g., in the form of ointments, creams or oils. Oral administration is particular.
  • The production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules). Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
  • Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
  • The dosage of the compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 1000 mg, especially about 1 to 300 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g., in 1 to 3 dosage units.
  • The pharmaceutical preparations conveniently contain about 1-500 mg, particularly 1-100 mg, of a compound of formula I.
  • The following examples serve to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner.
    • EXAMPLES Abbreviations
  • DCC=N,N′-diisopropyl-carbodiimide, DIEA=diisopropylethylamine, DMAc=dimethylacetamide, DMAP=4-dimethylaminopyridine, DMF=N,N-dimethylformamide, DMSO=dimethyl sulfoxide, EDCI=N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide hydrochloride, HATU=1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate, HCl=hydrogen chloride, HPLC=high performance liquid chromatography, LDA=lithium diisopropylamide, MS=mass spectrum, NMR=nuclear magnetic resonance, TEA=triethylamine, and THF=tetrahydrofuran.
    • Synthesis of the intermediate 1-(2-Fluoro-5-nitro-phenyl)-propan-1-one J
  • To a solution of the 1-(2-Fluoro-phenyl)-propan-1-one (99 mmol) in concentrated sulfuric acid (80 ml) cooled down to −30° C. was added slowly fuming nitric acid (8 ml) over 20 min and the solution was stirred at −30° C. for 15 min. The mixture was slowly poured into a stirred mixture of 200 ml of water and 400 g ice. The aqueous phase was extracted with ethyl acetate, the organic layer was extracted again with water and aqueous NaHCO3 1M. The organic layer was dried over Na2SO4, evaporated and the residue was chromatographed on silica using a mixture of heptane and ethylacetate as eluent to afford 16.5 g of the pure nitro intermediate J. MS (ESI): m/z=198.1 [M+H]+.
    • A. Synthesis of the intermediate sulfinyl imines A General Procedure
  • To a solution of the (R)-(+)-tert-butylsulfinamide (89.8 mmol) in THF (400 ml) was added subsequently the ketone (98.7 mmol) and titanium(IV) ethoxide (178.4 mmol) and the solution was stirred at reflux temperature for 5 h. The mixture was cooled to 22° C., treated with brine (400 ml), the suspension was stirred for 10 min and filtered over dicalite. The layers were separated, the aqueous layer was extracted with ethyl acetate, the combined organic layers were washed with water, dried and evaporated. The residue was chromatographed on silica using a mixture of heptane and ethyl acetate as eluent to give the pure sulfinyl imine A.
  • Intermediate A1 (R3=Me): Starting from 1-(2-fluoro-5-nitro-phenyl)-ethanone (89.7 mmol), the product (R)-2-methyl-propane-2-sulfinic acid [1-(2-fluoro-5-nitro-phenyl)-(E)-ethylidene]-amide (21.56 g) was obtained as a pale yellow solid. MS (ESI): m/z=287.0 [M+H]+.
  • Intermediate A2 (R3=Et): Starting from 1-(2-fluoro-5-nitro-phenyl)-propan-1-one (91 mmol), the product (R)-2-methyl-propane-2-sulfinic acid [1-(2-fluoro-5-nitro-phenyl)-(E)-propylidene]-amide (21.9 g) was obtained as a pale yellow solid. MS (ESI): m/z=301.1 [M+H]+.
    • B. Synthesis of the intermediate sulfinamide esters B General Procedure
  • To a solution of diisopropylamide (7.95 ml) in THF (100 ml) was added at −78° C. n-butyllithium (1.6 M solution in hexane, 35.4 ml) and stirring was continued at −78° C. for 30 min. The solution was treated with methyl acetate (4.51 ml) and after 30 min a solution of chlorotriisopropoxytitanium (15.6 g) in THF (20 ml) was added and stirring was continued at −78° C. for 30 min. The mixture was treated with a solution of the sulfinyl imine A (17.1 mmol) in THF (10 ml) and stirring was continued at −78° C. for 3 h. The mixture was quenched with saturated aqueous NH4Cl solution (150 ml) and the mixture was filtered over dicalite. The layers were separated, the aqueous layer was extracted with ethyl acetate, the combined organic layers were washed with water, dried and evaporated. The residue was chromatographed on silica using a mixture of heptane and ethylacetate as eluent to give the pure sulfinamide ester B.
  • Intermediate B1 (R3=Me): Starting from (R)-2-methyl-propane-2-sulfinic acid [1-(2-fluoro-5-nitro-phenyl)-(E)-ethylidene]-amide (17 mmol), the product (S)-3-(2-fluoro-5-nitro-phenyl)-3-((R)-2-methyl-propane-2-sulfinylamino)-butyric acid methyl ester (4.09 g) was obtained as a pale yellow solid. MS (ESI): m/z=361.0 [M+H]+.
  • Intermediate B2 (R3=Et): Starting from (R)-2-methyl-propane-2-sulfinic acid [1-(2-fluoro-5-nitro-phenyl)-(E)-propylidene]-amide (36 mmol), the product (S)-3-(2-fluoro-5-nitro-phenyl)-3-((R)-2-methyl-propane-2-sulfinylamino)-pentanoic acid methyl ester (3.73 g) was obtained as a pale yellow solid. MS (ESI): m/z=375.3 [M+H]+.
  • Intermediate Ba3 (R1,2=cyclopropyl, R3=Me): To a solution of diisopropylamine (24.5 ml) in THF (300 ml) was added at −20° C. n-butyllithium (1.6 M solution in hexane, 109 ml), the mixture was warmed to 0° C. for 30 min and cooled to −78° C. The solution was treated with a solution of cyclopropanecarboxylic acid tert-butyl ester (24.8 g, preparation described in St. W. Wright et al., Tetrahedron Lett. 38, 7345 1997) in THF (50 ml) and after stirring for 4 h at −78° C. a solution of (R)-2-methyl-propane-2-sulfinic acid [1-(2-fluoro-5-nitro-phenyl)-(E)-ethylidene]-amide (50.0 g) in THF (50 ml) was added and stirring was continued for 4 h. The mixture was quenched with brine, extracted with ethyl acetate, the organic layer was dried and evaporated. The residue was purified by chromatography over silica using cyclohexane/ethylacetate (4:1) to give 1-[(S)-1-(2-fluoro-5-nitro-phenyl)-1-(R)-2-methyl-propane-2-sulfinylamino)-ethyl]-cyclopropanecarboxylic acid tert-butyl ester (17.3 g) as a pale brown oil. MS (ESI): m/z=429.3 [M+H]+.
  • Figure US20110144098A1-20110616-C00013
    • C. Synthesis of the intermediate amino esters C General Procedure
  • A solution of the sulfinamide ester B (4.21 mmol) in methanol (40 ml) was treated with a solution of HCl in 1,4-dioxane (4 M, 53 ml) and stirring was continued at 22° C. for 2 h. The mixture was evaporated and the residue was partitioned between ethyl acetate and aqueous Na2CO3 2M. The organic layer was dried and evaporated to give a residue which was chromatographed on silica using a mixture of heptane and ethal acetate as eluent to give the pure aminoester C.
  • Intermediate C1 (R3=Me): Starting from (S)-3-(2-fluoro-5-nitro-phenyl)-3-(R)-2-methyl-propane-2-sulfinylamino)-butyric acid methyl ester (12 mmol), the product (S)-3-amino-3-(2-fluoro-5-nitro-phenyl)-butyric acid methyl ester (2.76 g) was obtained as a pale yellow solid.
  • MS (ESI): m/z=257.3 [M+H]+.
  • Intermediate C2 (R3=Et): Starting from (S)-3-(2-fluoro-5-nitro-phenyl)-3-((R)-2-methyl-propane-2-sulfinylamino)-pentanoic acid methyl ester (7 mmol), the product (S)-3-amino-3-(2-fluoro-5-nitro-phenyl)-pentanoic acid methyl ester (1.31 g) was obtained as a pale yellow solid. MS (ESI): m/z=271.1 [M+H]+.
  • Intermediate Ca3: (R1,2=cyclopropyl, R3=Me): A solution of 1-[(S)-1-(2-fluoro-5-nitro-phenyl)-1-((R)-2-methyl-propane-2-sulfinylamino)-ethyl]-cyclopropanecarboxylic acid tert-butyl ester (3.0 g) in HCl/AcOEt (2M, 35 ml) was heated in a sealed tube to 65° C. for 5.5 h. The suspension was diluted with diisopropyl ether (70 ml), stirred for 1 h, filtered and the residue was dried to give the hydrochloride of 1-[(S)-1-amino-1-(2-fluoro-5-nitro-phenyl)-ethyl]-cyclopropanecarboxylic acid (2.03 g) as a pale brown solid. MS (ESI): m/z=269.2 [M+H]+.
  • Figure US20110144098A1-20110616-C00014
    • D. Synthesis of the intermediate amino alcohol D
  • Procedure for intermediate D1 (R3=Me): (S)-3-Amino-3-(2-fluoro-5-nitro-phenyl)-butan-1-ol: A solution of the (S)-3-amino-3-(2-fluoro-5-nitro-phenyl)-butyric acid methyl ester (11.0 mmol) in 300 mL ether cooled down to −35° C. was treated with lithium aluminiumhydride (33.0 mmol) and stirring was continued at −35° C. for 90 min. The reaction mixture was then cooled down to −55° C., quenched by addition of 60 g of Na2SO4×10 H2O and vigorously stirred. Filtration on dicalite, filter cake washed with Ether and collected filtrate was concentrated under vacuo to afford an oil. The residue was chromatographed on silica using a mixture of heptane and ethyl acetate as eluent to give 1.53 g of the pure amino alcohol D1. MS (ESI): m/z=229.4 [M+H]+.
  • Procedure for intermediate D2 (R3=Et): (S)-3-Amino-3-(2-fluoro-5-nitro-phenyl)-pentan-1-ol: A solution of the (S)-3-amino-3-(2-fluoro-5-nitro-phenyl)-pentanoic acid methyl ester (4.4 mmol) in 24 mL dry THF cooled down to 0° C. was treated with lithium borohydride (9.0 mmol) and stirring was continued at 0° C. for 15 min. The reaction mixture was then let to warm up to room temperature and stirred for an additional 5 h. The reaction was quenched by addition of water, reaction volume was reduced in vacuo and diluted with ethylacetate. The organic phase was extracted with aqueous NaOH 1M, dried over Na2SO4 and evaporated to give a residue which was chromatographed on silica using a mixture of dichloromethane and a solution 10% NH4OH in MeOH as eluent to give 0.76 g of the (S)-3-amino-3-(2-fluoro-5-nitro-phenyl)-pentan-1-ol. MS (ESI): m/z=243.0 [M+H]+.
  • Procedure for intermediate Da3 (R1,2=cyclopropyl, R3=Me): A solution of the hydrochloride of 1-[(S)-1-amino-1-(2-fluoro-5-nitro-phenyl)-ethyl]-cyclopropanecarboxylic acid (1.8 g) in THF (10 ml) was cooled to 0° C. and treated with a solution of BH3-THF complex in THF (1M, 22.7 ml) and stirring was continued at 0° C. for 3 h. The reaction mixture was pored into crashed ice/saturated aqueous NaHCO3 (1/1, 200 ml), extracted with ethyl acetate, the organic layer was dried and evaporated to give crude {1-[(S)-1-amino-1-(2-fluoro-5-nitro-phenyl)-ethyl]-cyclopropyl}-methanol as a pale yellow solid. MS (ESI): m/z=255.2 [M+H]+.
  • Figure US20110144098A1-20110616-C00015
    • E. Synthesis of the intermediate amino oxazine E General Procedure
  • To a solution of the amino alcohol D (5.4 mmol) in 30 mL dry THF was added bromocyanogen (6.2 mmol), sodium acetate (6.2 mmol) and the resulting reaction mixture was stirred at 80° C. overnight. The reaction mixture was let to cool down to room temperature, followed by addition of HCl 4.0M in Dioxane (10 mL) and stirred for 20 min. The reaction volume reduced in vacuo, diluted with ethyl acetate and partitioned with aq. Na2CO3 2M solution. The organic layer was dried and evaporated down to dryness to give a residue which was chromatographed on silica using a mixture of heptane and ethyl acetate as eluent to afford pure amino oxazine E.
  • Intermediate E1 (R3=Me): Starting from (S)-3-amino-3-(2-fluoro-5-nitro-phenyl)-butan-1-ol (5 mmol), the product (S)-4-(2-fluoro-5-nitro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine (1.04 g) was obtained as a pale yellow solid. MS (ESI): m/z=254.0 [M+H]+.
  • Intermediate E2 (R3=Et): Starting from (S)-3-amino-3-(2-fluoro-5-nitro-phenyl)-pentan-1-ol (2 mmol), the product (S)-4-ethyl-4-(2-fluoro-5-nitro-phenyl)-5,6-dihydro-4H-[1,3]oxazin-2-ylamine (0.253 g) was obtained as a pale yellow solid. MS (ESI): m/z=268.1 [M+H]+.
  • Intermediate Ea3 (R1,2=cyclopropyl, R3=Me): To a solution of {1-[(S)-1-amino-1-(2-fluoro-5-nitro-phenyl)-ethyl]-cyclopropyl}-methanol (0.50 g) in dry THF (20 ml) was added bromocyanogen (0.24 g) and sodium acetate (0.19 g) and the mixture was stirred at 80° C. overnight. The mixture was cooled to 22° C., diluted with HCl in dioxane (4M, 2.4 ml) and stirring was continued for 1 h. The mixture was partitioned between aqueous saturated Na2CO3 and ethyl acetate, the organic layer was dried, evaporated and the residue purified by chromatography over silca-NH2 using ethyl acetate to give (S)-8-(2-fluoro-5-nitro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine (0.30 g) as a pale yellow solid. MS (ESI): m/z=280.1 [M+H]+.
  • Figure US20110144098A1-20110616-C00016
    • F. Synthesis of the intermediate Boc-protected amino oxazine F General Procedure
  • To a solution of the amino oxazine E (1.7 mmol) in 25 mL dry THF was added di-tert-butyl dicarbonate (2.0 mmol), diisopropylethylamine (2.0 mmol) and the resulting reaction mixture was stirred at 40° C. overnight. The reaction mixture was let to cool down to room temperature and the reaction mixture was concentrated in vacuo to give a white foam. The residue was chromatographed on silica using a mixture of heptane and ethyl acetate as eluent to give pure Boc-protected amino oxazine F.
  • Intermediate F1 (R3=Me): Starting from (S)-4-(2-fluoro-5-nitro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine (2 mmol), the product [(S)-4-(2-fluoro-5-nitro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester (0.473 g) was obtained as a pale yellow solid. MS (ESI): m/z=354.1 [M+H]+.
  • Intermediate F2 (R3=Et): Starting from (S)-4-ethyl-4-(2-fluoro-5-nitro-phenyl)-5,6-dihydro-4H-[1,3]oxazin-2-ylamine (1 mmol), the product [(S)-4-ethyl-4-(2-fluoro-5-nitro-phenyl)-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester (0.296 g) was obtained as a pale yellow solid. MS (ESI): m/z=368.1 [M+H]+.
    • F. Synthesis of the intermediate aniline Fa
  • Intermediate Fa3 (R1,2=cyclopropyl, R3=Me): A suspension of (S)-8-(2-fluoro-5-nitro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine (279 mg) in ethyl alcohol (25 ml), NEt3 (0.10 ml) and Pd/C (10%, 50 mg) was hydrogenated at normal pressure and 22° C. for 1 h. The mixture was filtered, the filtrate evaporated and the residue triturated with ether to give (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine (213 mg) as a pale yellow solid. MS (ESI): m/z=250.1 [M+H]+.
  • Figure US20110144098A1-20110616-C00017
    • Synthesis of the intermediate anilines G General Procedure
  • A suspension of the Boc-protected amino oxazine F (3.3 mmol) in ethanol (100 ml) and Pd/C (10%, 100 mg) was hydrogenated at normal pressure and 22° C. for 2 h. The mixture was filtered on dicalite, the filtrate evaporated and the residue was chromatographed on silica using a mixture of dichloromethane and methanol as eluent to give the pure aniline F.
  • Intermediate G1 (R3=Me): Starting from [(S)-4-(2-fluoro-5-nitro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester (1.34 mmol), the product [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester 0.43 g) was obtained as a pale yellow solid. MS (ESI): m/z=324.5 [M+H]+.
  • Intermediate G (R3=Et): Starting from [(S)-4-ethyl-4-(2-fluoro-5-nitro-phenyl)-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester (0.8 mmol), the product [(S)-4-(5-Amino-2-fluoro-phenyl)-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester (0.247 g) was obtained as a pale yellow solid. MS (ESI): m/z=338.2 [M+H]+.
    • Synthesis of the amides H and I General Procedure
  • To a solution of the aniline G (0.32 mmol) in dry dichloromethane (5 ml) was added subsequently EDCI (0.35 mmol), the carboxylic acid (0.35 mmol) and stirring was continued at 22° C. for 16 h. The mixture was purified on prep. RP-18 HPLC using a gradient of acetonitrile and water (containing 0.1% of triethylamine) to give the t-butyloxycarbonyl protected intermediate H.
  • A solution of t-butyloxycarbonyl protected intermediate H (0.27 mmol) in 4.0 ml dry dichloromethane was added CF3COOH (1 ml) and stirring was continued at 22° C. for 90 min. The mixture was evaporated, the residue was dissolved in DMSO and purified by prep. RP-18 HPLC using a gradient of acetonitrile and water (containing 0.1% of triethylamine) to give the pure amide I in yields of 10-70%.
  • General procedure for the coupling of the intermediate aniline Fa and a carboxylic acid to give the final product I
  • To a solution of the carboxylic acid (0.12 mmole) in methanol (0.6 ml) was added at 0° C. 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride (0.12 mmole) and the solution was stirred for 60 min. The mixture was treated with the aniline Fa (0.12 mmole) and stirring was continued at 0° C. for 24 h. The mixture was evaporated and the residue partitioned between aqueous saturated Na2CO3 and ethyl acetate, the organic layer was dried and evaporated and the residue purified on prep. RP-18 HPLC using a gradient of acetonitrile and water (containing 0.1% of triethylamine) or NH2-silica using ethyl actetate/n-heptane to give the pure final product I.
    • Example 1 3,5-Dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00018
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 3,5-dichloro-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=398.1 [M+H]+.
    • Example 2 5-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00019
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 5-chloro-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound. MS (ESI): m/z=363.1 [M+H]+.
    • Example 3 5-Fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00020
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 5-fluoro-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound. MS (ESI): m/z=347.0 [M+H]+.
    • Example 4 Pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00021
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound. MS (ESI): m/z=329.0 [M+H]+.
    • Example 5 5-Trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00022
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 5-trifluoromethyl-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=397.0 [M+H]+.
    • Example 6 3-Fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00023
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F (R3=Me) and 3-fluoro-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=347.1.0 [M+H]+.
    • Example 7 5-Fluoro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00024
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 5-fluoro-thiophene-2-carboxylic acid followed by deprotection using procedure H yielded the title compound. MS (ESI): m/z=352.0 [M+H]+.
    • Example 8 2-Methyl-oxazole-4-carboxylic acid [3-(S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00025
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 2-methyl-oxazole-4-carboxylic acid followed by deprotection using procedure H yielded the title compound. MS (ESI): m/z=333.0 [M+H]+.
    • Example 9 4-Chloro-pyridine-2-carboxylic acid [3-(S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00026
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 4-chloro-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=363.1 [M+H]+.
    • Example 10 5-Chloro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00027
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F (R3=Me) and 5-chloro-thiophene-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=368.0 [M+H]+.
    • Example 11 Thieno[2,3-c]pyridine-7-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00028
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F (R3=Me) and thieno[2,3-c]pyridine-7-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=385.0 [M+H]+.
    • Example 12 3-Phenyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00029
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 3-phenyl-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=405.0 [M+H]+.
    • Example 13 Benzo[b]thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00030
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and benzo[b]thiophene-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=384.1 [M+H]+.
    • Example 14 5-Chloro-pyrazine-2-carboxylic acid [3-(S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00031
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 5-chloro-pyrazine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=364.0 [M+H]+.
    • Example 15 5-Methyl-pyridine-2-carboxylic acid [3-(S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00032
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 5-methyl-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=343.1 [M+H]+.
    • Example 16 3-Trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00033
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 3-trifluoromethyl-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound. MS (ESI): m/z=397.0 [M+H]+.
    • Example 17 5-Methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00034
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 5-methyl-thiophene-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=348.1.0 [M+H]+.
    • Example 18 Pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00035
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F2 (R3=Et) and pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=343.1 [M+H]+.
    • Example 19 5-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00036
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F2 (R3=Et) and 5-chloro-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=377.0 [M+H]+.
    • Example 20 5-Methyl-thiophene-2-carboxylic acid [3-(S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00037
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F2 (R3=Et) and 5-methyl-thiophene-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=362.0 [M+H]+.
    • Example 21 5-Chloro-thiophene-2-carboxylic acid [3-(S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00038
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F2 (R3=Et) and 5-chloro-thiophene-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=382.1 [M+H]+.
    • Example 22 3,5-Dichloro-pyridine-2-carboxylic acid [3-(S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00039
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F2 (R3=Et) and 3,5-Dichloro-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=411.0 [M+H]+.
    • Example 23 5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-(S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00040
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F2 (R3=Et) and 5-chloro-3-methyl-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=391.1 [M+H]+.
    • Example 24 2-Methyl-oxazole-4-carboxylic acid [3-(S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00041
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F2 (R3=Et) and 2-methyl-oxazole-4-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=347.0 [M+H]+.
    • Example 25 5-Cyano-pyridine-2-carboxylic acid [3-(S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00042
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R1=Me) and 5-cyano-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=354.1 [M+H]+.
    • Example 26 5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00043
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R1=Me) and 5-chloro-3-methyl-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound. MS (ESI): m/z=377.0 [M+H]+.
    • Example 27 3-Methoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00044
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F (R1=Me) and 3-methoxy-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=359.0 [M+H]+.
    • Example 28 2-Methyl-thiazole-4-carboxylic acid [3-(S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00045
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 2-methyl-thiazole-4-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=349.0 [M+H]+.
    • Example 29 1-Methyl-1H-pyrazole-3-carboxylic acid [3-(S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00046
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R3=Me) and 1-methyl-1H-pyrazole-3-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=332.0 [M+H]+.
    • Example 30 5-Methoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00047
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R1=Me) and 5-methoxy-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=359.0 [M+H]+.
    • Example 31 3-Chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00048
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R1=Me) and 3-chloro-5-trifluoromethyl-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound. MS (ESI): m/z=431.0 [M+H]+.
    • Example 32 6-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00049
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R1=Me) and 6-chloro-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=363.0 [M+H]+.
    • Example 33 3,5-Difluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00050
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R1=Me) and 3,5-difluoro-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=365.0 [M+H]+.
    • Example 34 3-Methyl-thiophene-2-carboxylic acid [3-(S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00051
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R1=Me) and 3-methyl-thiophene-2-carboxylic acid followed by deprotection using procedure H yielded the title compound.
  • MS (ESI): m/z=384.0 [M+H]+.
    • Example 35 3-Chloro-5-fluoro-pyridine-2-carboxylic acid [3-(S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00052
  • The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester from experiment F1 (R1=Me) and 3-chloro-5-fluoro-pyridine-2-carboxylic acid followed by deprotection using procedure H yielded the title compound. MS (ESI): m/z=381.0 [M+H]+.
    • Example 36 5-Chloro-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00053
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 5-chloro-pyridine-2-carboxylic acid yielded the title compound as a white solid. MS (ESI): m/z=389.2 [M+H]+.
    • Example 37 3-Fluoro-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00054
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 3-fluoro-pyridine-2-carboxylic acid yielded the title compound as a colorless solid. MS (ESI): m/z=373.2 [M+H]+.
    • Example 38 5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-Spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]amide
  • Figure US20110144098A1-20110616-C00055
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 5-chloro-3-methyl-pyridine-2-carboxylic acid yielded the title compound as a colorless solid. MS (ESI): m/z=403.4 [M+H]+.
    • Example 39 5-Methoxy-pyridine-2-carboxylic acid [3-(S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00056
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 5-methoxy-pyridine-2-carboxylic acid yielded the title compound as a colorless oil. MS (ESI): m/z=385.3 [M+H]+.
    • Example 40 5-Fluoro-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00057
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 5-fluoro-pyridine-2-carboxylic acid yielded the title compound as a colorless oil. MS (ESI): m/z=373.2 [M+H]+.
    • Example 41 5-Cyano-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00058
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 5-cyano-pyridine-2-carboxylic acid yielded the title compound as a colorless solid. MS (ESI): m/z=380.2 [M+H]+.
    • Example 42 5-Difluoromethoxy-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-Spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00059
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 5-difluoromethoxy-pyridine-2-carboxylic acid (prepared according to Suzuki, Y. et al., Int. Patent Appl. WO2009091016) yielded the title compound as a colorless solid.
  • MS (ESI): m/z=421.1 [M+H]+.
    • Example 43 Pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00060
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and pyridine-2-carboxylic acid yielded the title compound as a colorless solid.
  • MS (ESI): m/z=355.2 [M+H]+.
    • Example 44 5-Chloro-pyrimidine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00061
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 5-chloro-pyrimidine-2-carboxylic acid yielded the title compound as a colorless solid. MS (ESI): m/z=390.2 [M+H]+.
    • Example 45 N-[3-((S)-2-Amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-2,3,3,3-tetrafluoro-propionamide
  • Figure US20110144098A1-20110616-C00062
  • The coupling of (S)-4-(5-Amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine and 2,3,3,3-tetrafluoro-propionic acid yielded the title compound as colorless solid.
  • MS (ESI): m/z=352.1 [M+H]+.
    • Example 46 2,2-Difluoro-cyclopropanecarboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00063
  • The coupling of (S)-4-(5-Amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine and 2,2-difluoro-cyclopropanecarboxylic acid yielded the title compound as colorless solid. MS (ESI): m/z=328.2 [M+H]+.
    • Example 47 (S)-N-(3-(6-Amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-2,6-difluorobenzamide
  • Figure US20110144098A1-20110616-C00064
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 2,6-difluoro-benzoic acid yielded the title compound as a yellow solid.
  • MS (ESI): m/z=390.3 [M+H]+.
    • Example 48 (S)-N-(3-(6-Amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-chloropicolinamide
  • Figure US20110144098A1-20110616-C00065
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 3-chloro-pyridine-2-carboxylic acid yielded the title compound as a yellow solid. MS (ESI): m/z=389.2 [M+H]+.
    • Example 49 (S)-N-(3-(6-Amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3,5-difluoropicolinamide
  • Figure US20110144098A1-20110616-C00066
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 3,5-difluoro-pyridine-2-carboxylic acid yielded the title compound as a yellow solid. MS (ESI): m/z=391.3 [M+H]+.
    • Example 50 (S)-N-(3-(6-Amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-chloro-5-(trifluoromethyl)picolinamide
  • Figure US20110144098A1-20110616-C00067
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 3-chloro-5-trifluoromethyl-pyridine-2-carboxylic acid yielded the title compound as a yellow solid. MS (ESI): m/z=457.3 [M+H]+.
    • Example 51 (S)-N-(3-(6-Amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-(trifluoromethyl)picolinamide
  • Figure US20110144098A1-20110616-C00068
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 3-trifluoromethyl-pyridine-2-carboxylic acid yielded the title compound as a yellow solid. MS (ESI): m/z=423.2 [M+H]+.
    • Example 52 (S)-N-(3-(6-Amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-chloro-5-fluoropicolinamide
  • Figure US20110144098A1-20110616-C00069
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 3-chloro-5-fluoro-pyridine-2-carboxylic acid yielded the title compound as a yellow solid. MS (ESI): m/z=407.3 [M+H]+.
    • Example 53 (S)-N-(3-(6-Amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3,5-dichloropicolinamide
  • Figure US20110144098A1-20110616-C00070
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 3,5-dichloro-pyridine-2-carboxylic acid yielded the title compound as a pale yellow solid. MS (ESI): m/z=423.1 [M+H]+.
    • Example 54 (S)-N-(3-(6-Amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-1-(trifluoromethyl)cyclopropanecarboxamide
  • Figure US20110144098A1-20110616-C00071
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 1-trifluoromethyl-cyclopropanecarboxylic acid yielded the title compound as a pale yellow solid. MS (ESI): m/z=386.4 [M+H]+.
    • Example 55 N-(3-((S)-6-Amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-2,2-difluorocyclopropanecarboxamide
  • Figure US20110144098A1-20110616-C00072
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and rac-2,2-difluoro-cyclopropanecarboxylic acid yielded a mixture of epimers of the title compound as a yellow solid. MS (ESI): m/z=354.2 [M+H]+.
    • Example 56 (S)-N-(3-(6-Amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-4-chloro-1-methyl-1H-pyrazole-3-carboxamide
  • Figure US20110144098A1-20110616-C00073
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 4-chloro-1-methyl-1H-pyrazole-3-carboxylic acid yielded the title compound as a yellow solid. MS (ESI): m/z=392.2 [M+H]+.
    • Example 57 (S)-N-(3-(6-Amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-5-chloro-4-methylisoxazole-3-carboxamide
  • Figure US20110144098A1-20110616-C00074
  • The coupling of (S)-8-(5-amino-2-fluoro-phenyl)-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-6-ylamine and 5-chloro-4-methyl-isoxazole-3-carboxylic acid yielded the title compound as a pale yellow solid. MS (ESI): m/z=393.2 [M+H]+.
    • Example 58 1-Trifluoromethyl-cyclopropanecarboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00075
  • The coupling of (S)-4-(5-Amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine and 1-trifluoromethyl-cyclopropanecarboxylic acid yielded the title compound as colorless solid. MS (ESI): m/z=360.1 [M+H]+.
    • Example 59 N-[3-((S)-2-Amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-3,3,3-trifluoro-propionamide
  • Figure US20110144098A1-20110616-C00076
  • The coupling of (S)-4-(5-Amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine and 3,3,3-trifluoro-propionic acid yielded the title compound as colorless solid. MS (ESI): m/z=334.3 [M+H]+.
    • Example 60 (S)-N-(3-(2-Amino-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-3-(2,2,2-trifluoroethoxy)picolinamide
  • Figure US20110144098A1-20110616-C00077
  • The 3-(2,2,2-trifluoro-ethoxy)-pyridine-2-carboxylic acid was prepared as follows:
  • a) To a solution of 3-hydroxy-pyridine-2-carboxylic acid methyl ester (200 mg, 1.3 mmol) in N,N-dimethylformamide (2.0 ml) was added at 22° C. sodium hydride (55% in oil, 64 mg) and stirring was continued until gas evolution ceased. The suspension was cooled to 0° C. and treated with trifluoroethyl trifluormethanesulfonate (728 mg) and stirring was continued at 22° C. for 2 hours. The mixture was partitioned between saturated sodium hydrogen-carbonate solution and ethyl acetate, and the organic layer was dried and evaporated. The residue was purified by chromatography on silica using n-heptane and ethyl acetate (3:1) as the eluent to give 3-(2,2,2-trifluoro-ethoxy)-pyridine-2-carboxylic acid methyl ester as a pale green oil. MS (ESI): m/z=236.2 [M+H]+.
    b) A solution of 3-(2,2,2-trifluoro-ethoxy)-pyridine-2-carboxylic acid methyl ester (216 mg, 0.9 mmol) in methanol (1 ml) was treated with a solution of lithium hydroxide (78 mg, 3.3 mmol) in water (0.1 ml) and stirring was continued at 22° C. for 2 hours. The solution was evaporated and the residue triturated with 1N aqueous hydrochloric acid. The suspension was filtered, the residue washed with water and dried to give 3-(2,2,2-trifluoro-ethoxy)-pyridine-2-carboxylic acid as a colorless solid. MS (ESI): m/z=220.0 [M−H]−.
    c) The coupling of [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tent-butyl ester and 3-(2,2,2-trifluoro-ethoxy)-pyridine-2-carboxylic acid yielded the title compound as a white powder. MS (ESI): m/z=427.1 [M+H]+.
    • Example 61 5-Difluoromethoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00078
  • The coupling of (S)-4-(5-Amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine and 5-difluoromethoxy-pyridine-2-carboxylic acid yielded the title compound as colorless solid. MS (ESI): m/z=395.0 [M+H]+.
    • Example 62 3-Methyl-oxetane-3-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00079
  • The coupling of (S)-4-(5-Amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine and 3-methyl-oxetane-3-carboxylic acid yielded the title compound as colorless solid.
  • MS (ESI): m/z=322.0 [M+H]+.
    • Example 63 4-Methyl-isoxazole-3-carboxylic acid [3-(S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00080
  • The coupling of (S)-4-(5-Amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine and 4-methyl-isoxazole-3-carboxylic acid yielded the title compound as colorless solid. MS (ESI): m/z=333.3 [M+H]+.
    • Example 64 4-Chloro-1H-pyrazole-3-carboxylic acid [3-(S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00081
  • The coupling of (S)-4-(5-Amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine and 4-chloro-1H-pyrazole-3-carboxylic acid yielded the title compound as colorless solid. MS (ESI): m/z=352.0 [M+H]+.
    • Example 65 5-Chloro-pyridine-2-carboxylic acid [3-((4aS,7aS)-2-amino-4a,5-dihydro-4H-furo[3,4-d][1,3]oxazin-7a-yl)-4-fluoro-phenyl]-amide
  • Figure US20110144098A1-20110616-C00082
    • Synthesis of the Intermediate K
  • Figure US20110144098A1-20110616-C00083
  • To a solution of rac-(4S,4aS)-7a-(2-fluoro-phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]oxazin-2-ylamine (1.7 mmole, intermediate J, preparation described in WO 2009091016) in THF (20 ml) was added subsequently sodium acetate (1.9 mmole) and cyanogen bromide (1.9 mmole) and the reaction mixture was heated at 80° C. for 8 h. The reaction mixture was quenched with water (20 ml), the aqueous layer was extracted with EtOAc, the organic layer was washed with brine, dried over Na2SO4, filtered and the filtrate was evaporated. The residue was purified by chromatography on silica using dichloromethane/methanol (99:1) to give rac-(4S,4aS)-7a-(2-fluoro-phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]oxazin-2-ylamine (56 mg) as a colorless gum.
    • Synthesis of Intermediate Ea
  • Figure US20110144098A1-20110616-C00084
  • To a solution of rac-(4S,4aS)-7a-(2-fluoro-phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]oxazin-2-ylamine (0.21 mmol) in sulfuric acid (98%, 1 ml) was added at 0° C. fuming nitric acid (0.014 ml) and the reaction mixture was allowed to warm to 25° C. over 30 min. The mixture was slowly added to 5 ml ice cold water, the pH was adjusted to 7 using aqueous 2N NaOH and extracted with dichloromethane. The organic layer was washed with brine, dried over Na2SO4, filtered and the filtrate was evaporated to give crude rac-(4S,4aS)-7a-(2-fluoro-5-nitro-phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]oxazin-2-ylamine (50 mg) as a light yellow foam.
    • Synthesis of intermediate Fa
  • Figure US20110144098A1-20110616-C00085
  • To a solution of rac-(4S,4aS)-7a-(2-fluoro-5-nitro-phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]oxazin-2-ylamine (0.18 mmol) in methanol (5 ml) and triethylamine (0.25 ml) was added Pd/C (10%, 189 mg) and the mixture was hydrogenated at atmospheric pressure for 1 h. The mixture was filtered over dicalite, the filtrate evaporated and the residue purified by chromatography on silica using a gradient of dichloromethane/methanol to yield pure rac-(4S,4aS)-7a-(5-mino-2-fluoro-phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]oxazin-2-ylamine (12 mg) as a colorless waxy solid. MS (ESI): m/z=252.2 [M+H]+.
  • To a solution of 5-chloro-pyridine-2-carboxylic acid (0.048 mmole) in MeOH (0.3 ml) was added at 0° C. 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM, 0.062 mmole), the reaction mixture was stirred at 0° C. for 5 min. followed by the addition of a solution of rac-(4S,4aS)-7a-(5-amino-2-fluoro-phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]oxazin-2-ylamine (0.048 mmol) in MeOH (0.4 ml) at 0° C. and stirring was continued at this temperature for 4 h. The reaction mixture was evaporated, the residue partitioned between aqueous NaOH (1N, 0.3 ml) and EtOAc, the organic layers was dried over Na2SO4, filtered and the filtrate was evaporated. The residue was triturated with diethyl ether and dried to give the pure title compound (10 mg) as a white solid. MS (ESI): m/z=391.1 [M+H]+.
    • Example 66
  • The following test was carried out in order to determine the activity of the compounds of the present invention.
    • Assay for BACE Inhibition by Measuring Cellular TMEM27 Cleavage
  • The assay uses the principle of inhibition of human TMEM27 cleavage by endogenous cellular BACE2 in the Ins1e rat cell line and shedding from the cell surface into the culture medium, followed by detection in an ELISA assay. Inhibition of BACE2 prevents the cleavage and shedding in a dose-dependent manner.
  • The stable cell line “INS-TMEM27” represents an INS1e-derived cell line with inducible expression (using the TetOn system) of full-length hTMEM27 in a doxycycline-dependent manner. The cells were cultured throughout the experiment in RPMI1640+Glutamax (Invitrogen) Penicillin/Streptomycin, 10% Fetal bovine serum, 100 mM pyruvate, 5 mM beta-mercaptoethanol, 100 micrograms/ml G418 and 100 microgram/ml hygromycin and were grown in adherent culture at 37° C. in a standard CO2 cell culture incubator.
  • INS-TMEM27 cells were seeded in 96-well plates. After 2 days in culture, BACE2 inhibitor was added in a range of concentrations as required by the assay and after a further two hours, doxycycline was added to a final concentration of 500 ng/ml. The cells were incubated for a further 46 hours and the supernatant harvested for detection of shed TMEM27.
  • An ELISA assay (using a pair of mouse anti-human-TMEM27 antibodies, raised against the extracellular domain of TMEM27) was used for detection of TMEM27 in the culture medium. An IC50 for BACE2 inhibition was calculated using the ELISA readout for each inhibitor concentration with standard curve-fitting software XLfit (IDBS) for the Excel spreadsheet program.
  • The particular compounds according to formula I have an inhibitory activity in the above assay (IC50) particularly of 5 nM to 50 μM, more particularly of 5 nM to 1 μM.
  • For example, the following compounds showed the following IC50 (BACE2) values in the assay described above:
  • TABLE 1
    IC50 values of selected examples
    Ex. IC50 [nM] Ex. IC50 [nM] Ex. IC50 [nM] Ex. IC50 [nM]
    1 4 18 35 35 11 52 16
    2 10 19 8 36 16 53 6
    3 6 20 48 37 40 54 810
    4 230 21 240 38 5.1 55 2100
    5 89 22 7 39 91 56 6
    6 19 23 9 40 39 57 6410
    7 340 24 1 41 52 58 700
    8 19 25 5 42 210 59 830
    9 143 26 1 43 18 60 143
    10 915 27 23 44 7.1 61 474
    11 28 28 4 45 400 62 9130
    12 34 29 3 46 70 63 104
    13 52 30 12 47 620 64 464
    14 190 31 11 48 36 65 60
    15 4.5 32 4 49 14
    16 22 33 7 50 190
    17 11 34 350 51 73
    • Example 67
  • Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
  • Ingredients Per tablet
    Kernel:
    Compound of formula I 10.0 mg 200.0 mg
    Microcrystalline cellulose 23.5 mg 43.5 mg
    Lactose hydrous 60.0 mg 70.0 mg
    Povidone K30 12.5 mg 15.0 mg
    Sodium starch glycolate 12.5 mg 17.0 mg
    Magnesium stearate 1.5 mg 4.5 mg
    (Kernel Weight) 120.0 mg 350.0 mg
    Film Coat:
    Hydroxypropyl methyl cellulose 3.5 mg 7.0 mg
    Polyethylene glycol 6000 0.8 mg 1.6 mg
    Talc 1.3 mg 2.6 mg
    Iron oxyde (yellow) 0.8 mg 1.6 mg
    Titan dioxide 0.8 mg 1.6 mg
  • The active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate is mixed with sodium starch glycolate and magnesiumstearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aqueous solution/suspension of the above mentioned film coat.
    • Example 68
  • Capsules containing the following ingredients can be manufactured in a conventional manner:
  • Ingredients Per capsule
    Compound of formula I 25.0 mg
    Lactose 150.0 mg
    Maize starch 20.0 mg
    Talc 5.0 mg
  • The components are sieved and mixed and filled into capsules of size 2.
    • Example 69
  • Injection solutions can have the following composition:
  •
    Compound of formula I 3.0 mg
    Polyethylene Glycol 400 150.0 mg
    Acetic Acid q.s. ad pH 5.0
    Water for injection solutions ad 1.0 ml
  • The active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part). The pH is adjusted to 5.0 by Acetic Acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.
    • Example 70
  • Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
  •
    Capsule contents
    Compound of formula I 5.0 mg
    Yellow wax 8.0 mg
    Hydrogenated Soya bean oil 8.0 mg
    Partially hydrogenated plant oils 34.0 mg
    Soya bean oil 110.0 mg
    Weight of capsule contents 165.0 mg
    Gelatin capsule
    Gelatin 75.0 mg
    Glycerol 85% 32.0 mg
    Karion 83 8.0 mg (dry matter)
    Titan dioxide 0.4 mg
    Iron oxide yellow 1.1 mg
  • The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures.
    • Example 71
  • Sachets containing the following ingredients can be manufactured in a conventional manner:
  •
    Compound of formula I 50.0 mg
    Lactose, fine powder 1015.0 mg
    Microcristalline cellulose 1400.0 mg
    (AVICEL PH 102)
    Sodium carboxymethyl cellulose 14.0 mg
    Polyvinylpyrrolidone K 30 10.0 mg
    Magnesiumstearate 10.0 mg
    Flavoring additives 1.0 mg
  • The active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water. The granulate is mixed with magnesium stearate and the flavouring additives and filled into sachets.

Claims (30)

1. A compound of formula I,
Figure US20110144098A1-20110616-C00086
wherein
R1 is hydrogen or C1-7-alkyl;
R2 is hydrogen or C1-7-alkyl;
or R1 and R2 together with the C atom they are attached to form a C3-7-cycloalkyl ring;
R3 is C1-7-alkyl or C3-7-cycloalkyl;
or R2 and R3 together with the C atoms they are attached to form a C3-7-cycloalkyl or a 3- to 7-membered O-heterocyclyl ring;
R4 is selected from the group consisting of hydrogen, C1-7-alkyl, halogen, cyano and C1-7-alkoxy; and
R5 is selected from the group consisting of:
i) aryl, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl,
ii) heteroaryl, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl,
iii) C1-7-alkyl, unsubstituted or substituted by one, two, three, four or five groups individually selected from the group consisting of halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano and hydroxy-C1-7-alkyl,
iv) a C3-7-cycloalkyl ring, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano and hydroxy-C1-7-alkyl, and
v) 3- to 7-membered O-heterocyclyl ring, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano and hydroxy-C1-7-alkyl,
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1,
Figure US20110144098A1-20110616-C00087
wherein
R1 is hydrogen or C1-7-alkyl;
R2 is hydrogen or C1-7-alkyl;
or R1 and R2 together with the C atom they are attached to form a C3-7-cycloalkyl ring;
R3 is C1-7-alkyl or C3-7-cycloalkyl;
or R2 and R3 together with the C atoms they are attached to form a C3-7-cycloalkyl or a 3- to 7-membered O-heterocyclyl ring;
R4 is selected from the group consisting of hydrogen, C1-7-alkyl, halogen, cyano and C1-7-alkoxy; and
R5 is aryl or heteroaryl, said aryl or heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl;
or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 1, wherein R1 and R2 together with the C atom they are attached to form a C3-7-cycloalkyl ring.
4. A compound according to claim 1, wherein R1 and R2 together with the C atom they are attached to form a cyclopropyl.
5. A compound according to claim 1, wherein R1 and R2 are each hydrogen.
6. A compound according to claim 1, wherein R3 is C1-7-alkyl.
7. A compound according to claim 1, wherein R3 is methyl.
8. A compound according to claim 1, wherein R3 is ethyl.
9. A compound according to claim 1, wherein R4 is halogen.
10. A compound according to claim 1, wherein R4 is fluoro.
11. A compound according to claim 1, wherein R5 is heteroaryl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl.
12. A compound according to claim 1, wherein R5 is heteroaryl selected from the group consisting of pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 6-oxo-1,6-dihydropyridazinyl, 5-oxo-4,5-dihydropyrazinyl, pyrrolyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, thieno[2,3-c]pyridyl, quinoxalinyl, benzo[b]thienyl, benzothiazolyl, benzotriazolyl, indolyl, indazolyl and 3,4-dihydro-1H-isoquinolinyl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl.
13. A compound according to claim 1, wherein R5 is heteroaryl selected from the group consisting of thienyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, 6-oxo-1,6-dihydropyridazinyl, 5-oxo-4,5-dihydropyrazinyl and imidazo[1,2-a]pyridyl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl.
14. A compound according to claim 1, wherein R5 is heteroaryl selected from the group consisting of thienyl, oxazolyl, pyridyl, pyrimidinyl and pyrazinyl, said heteroaryl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl.
15. A compound according to claim 1, wherein R5 is heteroaryl selected from the group consisting of thienyl, oxazolyl, pyridyl, pyrimidinyl and pyrazinyl substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl.
16. A compound according to claim 1, wherein R5 is heteroaryl selected from the group consisting of 1H-pyrazolyl, benzo[b]thiophenyl, isoxazolyl, oxazolyl, pyrazinyl, pyridinyl, pyrimidinyl, thiazolyl, thieno[2,3-c]pyridinyl and thiophenyl, said heteroaryl being unsubstituted or substituted by one or two groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkoxy, halogen-C1-7-alkyl, C1-7-alkoxy, cyano and phenyl.
17. A compound according to claim 1, wherein R5 is heteroaryl selected from the group consisting of 1H-pyrazolyl, thiazolyl, oxazolyl, pyridinyl, substituted by one or two substituents selected from the group consisting of C1-7-alkyl, halogen and cyano.
18. A compound according to claim 1, wherein R5 is heteroaryl selected from the group consisting of 1H-pyrazole-3-yl, benzo[b]thiophene-2-yl, isoxazole-3-yl, oxazole-4-yl, pyrazine-2-yl, pyridine-2-yl, pyrimidine-2-yl, thiazol-4-yl, thieno[2,3-c]pyridine-7-yl and thiophene-2-yl, said heteroaryl being unsubstituted or substituted by one or two groups selected from the group consisting of methyl, fluoro, chloro, difluoromethoxy, trifluoroethoxy, trifluoromethyl, methoxy, cyano and phenyl.
19. A compound according to claim 1, wherein R5 is phenyl, said phenyl being unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano, hydroxy-C1-7-alkyl, oxo and phenyl.
20. A compound according to claim 1, wherein R5 is phenyl, substituted by one or two halogens.
21. A compound according to claim 1, wherein R5 is C1-7-alkyl, unsubstituted or substituted by one, two, three, four or five halogens.
22. A compound according to claim 1, wherein R5 is ethyl, substituted by one, two, three, four or five fluoros.
23. A compound according to claim 1, wherein R5 is C3-7-cycloalkyl ring, unsubstituted or substituted by one, two or three groups selected from the group consisting of halogen and halogen-C1-7-alkyl.
24. A compound according to claim 1, wherein R5 is cyclopropyl, by one or two groups selected from the group consisting of fluoro and trifluoromethyl.
25. A compound according to claim 1, wherein R5 is 3- to 7-membered O-heterocyclyl ring, unsubstituted or substituted by one, two or three groups selected from the group consisting of C1-7-alkyl, halogen, halogen-C1-7-alkyl, C1-7-alkoxy, halogen-C1-7-alkoxy, cyano and hydroxy-C1-7-alkyl.
26. A compound according to claim 1, wherein R5 is oxetanyl, substituted by methyl.
27. A compound according to claim 1, selected from the group consisting of
3,5-Dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
Pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3-Fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Fluoro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
2-Methyl-oxazole-4-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
4-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Chloro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
Thieno[2,3-c]pyridine-7-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3-Phenyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
Benzo[b]thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Chloro-pyrazine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3-Trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
Pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Chloro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3,5-Dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
2-Methyl-oxazole-4-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Cyano-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3-Methoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
2-Methyl-thiazole-4-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
1-Methyl-1H-pyrazole-3-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Methoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3-Chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
6-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3,5-Difluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3-Methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3-Chloro-5-fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Chloro-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
3-Fluoro-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
5-Methoxy-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
5-Fluoro-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
5-Cyano-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
5-Difluoromethoxy-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
Pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
5-Chloro-pyrimidine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
N-[3-((S)-2-Amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-2,3,3,3-tetrafluoro-propionamide,
2,2-Difluoro-cyclopropanecarboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
(S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-2,6-difluorobenzamide,
(S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-chloropicolinamide,
(S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3,5-difluoropicolinamide,
(S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-chloro-5-(trifluoromethyl)picolinamide,
(S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-(trifluoromethyl)picolinamide,
(S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3-chloro-5-fluoropicolinamide,
(S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3,5-dichloropicolinamide,
(S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-1-(trifluoromethyl)cyclopropanecarboxamide,
N-(3-((S)-6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-2,2-difluorocyclopropanecarboxamide,
(S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-4-chloro-1-methyl-1H-pyrazole-3-carboxamide,
(S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-5-chloro-4-methylisoxazole-3-carboxamide,
1-Trifluoromethyl-cyclopropanecarboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
N-[3-((S)-2-Amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-3,3,3-trifluoro-propionamide,
(S)-N-(3-(2-amino-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-3-(2,2,2-trifluoroethoxy)picolinamide,
5-Difluoromethoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
(S)-N-(3-(2-amino-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-3-methyloxetane-3-carboxamide,
(S)-N-(3-(2-amino-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-4-methylisoxazole-3-carboxamide,
4-Chloro-1H-pyrazole-3-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide, and
5-Chloro-pyridine-2-carboxylic acid [3-((4aS,7aS)-2-amino-4a,5-dihydro-4H-furo[3,4-d][1,3]oxazin-7a-yl)-4-fluoro-phenyl]-amide,
or pharmaceutically acceptable salts thereof.
28. A compound according to claim 1, selected from the group consisting of
3,5-Dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
2-Methyl-oxazole-4-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Cyano-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
2-Methyl-thiazole-4-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
1-Methyl-1H-pyrazole-3-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
6-Chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3,5-Difluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-Chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-6-amino-8-methyl-5-oxa-7-aza-spiro[2.5]oct-6-en-8-yl)-4-fluoro-phenyl]-amide,
(S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-3,5-dichloropicolinamide, and
(S)-N-(3-(6-amino-8-methyl-5-oxa-7-azaspiro[2.5]oct-6-en-8-yl)-4-fluorophenyl)-4-chloro-1-methyl-1H-pyrazole-3-carboxamide,
or pharmaceutically acceptable salts thereof.
29. A compound according to claim 1, selected from the group consisting of
3,5-dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3-fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-fluoro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
2-methyl-oxazole-4-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
4-chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-chloro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
thieno[2,3-c]pyridine-7-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3-phenyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
benzo[b]thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-chloro-pyrazine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3-trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-chloro-thiophene-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3,5-dichloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
2-methyl-oxazole-4-carboxylic acid [3-((S)-2-amino-4-ethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-cyano-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-chloro-3-methyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3-methoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
2-methyl-thiazole-4-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
1-methyl-1H-pyrazole-3-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
5-methoxy-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3-chloro-5-trifluoromethyl-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
6-chloro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3,5-difluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
3-methyl-thiophene-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide, and
3-chloro-5-fluoro-pyridine-2-carboxylic acid [3-((S)-2-amino-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
or pharmaceutically acceptable salts thereof.
30. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier and/or adjuvant.
US12/958,436 2009-12-10 2010-12-02 Amino oxazine derivatives Expired - Fee Related US7964594B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09178642 2009-12-10
EP09178642.6 2009-12-10
EP09178642 2009-12-10

Publications (2)

Publication Number Publication Date
US20110144098A1 true US20110144098A1 (en) 2011-06-16
US7964594B1 US7964594B1 (en) 2011-06-21

Family

ID=43478012

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/958,436 Expired - Fee Related US7964594B1 (en) 2009-12-10 2010-12-02 Amino oxazine derivatives

Country Status (12)

Country Link
US (1) US7964594B1 (en)
EP (1) EP2509966B1 (en)
JP (2) JP2013513568A (en)
KR (1) KR101437750B1 (en)
CN (1) CN102652129A (en)
AR (1) AR079334A1 (en)
BR (1) BR112012013322A2 (en)
CA (1) CA2780693A1 (en)
MX (1) MX2012005810A (en)
RU (1) RU2012126083A (en)
TW (1) TW201125863A (en)
WO (1) WO2011070029A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142613A1 (en) * 2012-03-20 2013-09-26 Elan Pharmaceuticals, Inc. Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0617852A2 (en) 2005-10-25 2011-08-09 Shionogi & Co aminodihydrothiazine derivatives as well as compositions containing them
WO2008133273A1 (en) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Pharmaceutical composition for treatment of alzheimer's disease
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
NZ589590A (en) 2008-06-13 2012-05-25 Shionogi & Co Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
JPWO2010047372A1 (en) 2008-10-22 2012-03-22 塩野義製薬株式会社 2-Aminopyrimidin-4-one and 2-aminopyridine derivatives having BACE1 inhibitory activity
UY32799A (en) 2009-07-24 2011-02-28 Novartis Ag DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA108363C2 (en) 2009-10-08 2015-04-27 IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
US20120245155A1 (en) * 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
CA2783958A1 (en) * 2009-12-11 2011-06-16 Shionogi & Co., Ltd. Oxazine derivative
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
SI2663561T1 (en) 2011-01-13 2016-07-29 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8754075B2 (en) * 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
WO2012139425A1 (en) 2011-04-13 2012-10-18 Schering Corporation 5-substituted iminothiazines and their mono-and dioxides as bace inhibitors,compositions,and their use
EP2703399A4 (en) * 2011-04-26 2014-10-15 Shionogi & Co Oxazine derivative and bace 1 inhibitor containing same
US8785436B2 (en) * 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
US9079919B2 (en) * 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
KR20140041687A (en) 2011-06-07 2014-04-04 에프. 호프만-라 로슈 아게 Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
US9073909B2 (en) * 2011-06-07 2015-07-07 Hoffmann-La Roche Inc. [1,3]oxazines
JP2014524472A (en) 2011-08-22 2014-09-22 メルク・シャープ・アンド・ドーム・コーポレーション 2-Spiro-substituted iminothiazines and their monooxides and dioxides as BACE inhibitors, compositions, and uses thereof
UY34278A (en) 2011-08-25 2013-04-05 Novartis Ag NEW NOXEDINE DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF DISEASES
US20130073953A1 (en) * 2011-09-21 2013-03-21 Timothy Onyenobi News headline screenshot viewing system
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
JO3143B1 (en) * 2012-04-03 2017-09-20 Lilly Co Eli Tetrahydropyrrolothiazine compounds
US9556135B2 (en) 2012-10-12 2017-01-31 Amgen, Inc. Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9489013B2 (en) 2012-12-20 2016-11-08 Merck Sharp & Dohme Corp. C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use
AU2014223334C1 (en) 2013-03-01 2018-10-18 Amgen Inc. Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
CN105164121A (en) 2013-03-08 2015-12-16 美国安进公司 Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
US9045477B2 (en) * 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
KR20160002822A (en) * 2013-04-26 2016-01-08 에프. 호프만-라 로슈 아게 Synthesis of bace1 inhibitors
TW201623295A (en) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 Dihydrothiazine and dihydrooxazine derivatives having BACE1 inhibitory activity
MX2017001794A (en) 2014-08-08 2017-06-29 Amgen Inc Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use.
PE20171349A1 (en) 2015-03-20 2017-09-13 Hoffmann La Roche BACE1 INHIBITORS
WO2019208693A1 (en) 2018-04-27 2019-10-31 Shionogi & Co., Ltd. Tetrahydropyranooxazine derivatives having selective bace1 inhibitory activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759402B2 (en) * 1999-02-09 2004-07-06 University Of Virginia Patent Foundation Cyclic felbamate derived compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043916A1 (en) * 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
DE602005017033D1 (en) 2004-06-16 2009-11-19 Wyeth Corp AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR BETA SEKRETASE INHIBITION
WO2006041404A1 (en) * 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-compounds and uses thereof
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
BRPI0617852A2 (en) * 2005-10-25 2011-08-09 Shionogi & Co aminodihydrothiazine derivatives as well as compositions containing them
AU2008245082B8 (en) * 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
US8158620B2 (en) 2008-01-18 2012-04-17 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
GB0912778D0 (en) * 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
US20120245155A1 (en) * 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759402B2 (en) * 1999-02-09 2004-07-06 University Of Virginia Patent Foundation Cyclic felbamate derived compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142613A1 (en) * 2012-03-20 2013-09-26 Elan Pharmaceuticals, Inc. Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof

Also Published As

Publication number Publication date
WO2011070029A1 (en) 2011-06-16
US7964594B1 (en) 2011-06-21
AR079334A1 (en) 2012-01-18
TW201125863A (en) 2011-08-01
JP2013513568A (en) 2013-04-22
BR112012013322A2 (en) 2019-09-24
KR101437750B1 (en) 2014-09-03
KR20120103694A (en) 2012-09-19
CA2780693A1 (en) 2011-06-16
MX2012005810A (en) 2012-06-12
JP2015051992A (en) 2015-03-19
EP2509966A1 (en) 2012-10-17
EP2509966B1 (en) 2014-10-22
CN102652129A (en) 2012-08-29
RU2012126083A (en) 2014-01-20

Similar Documents

Publication Publication Date Title
US7964594B1 (en) Amino oxazine derivatives
US8461160B2 (en) Dihydropyrimidinones
US8815881B2 (en) 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds
US20140221360A1 (en) Use of aminodihydrothiazines for the treatment or prevention of diabetes
US9115098B2 (en) 1,3-oxazines as BACE1 and/or BACE2 inhibitors
US8927535B2 (en) Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors
KR20100131455A (en) Oxadiazoanthracene compounds for the treatment of diabetes

Legal Events

Date Code Title Description
AS Assignment

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BANNER, DAVID;HILPERT, HANS;MAUSER, HARALD;AND OTHERS;REEL/FRAME:025786/0451

Effective date: 20101109

Owner name: HOFFMANN-LA ROCHE, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:025786/0448

Effective date: 20101111

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20190621